<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Colchicine for acute gout - McKenzie, BJ - 2021 | Cochrane Library</title> <meta content="Colchicine for acute gout - McKenzie, BJ - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006190.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Colchicine for acute gout - McKenzie, BJ - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006190.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006190.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Colchicine for acute gout" name="citation_title"/> <meta content="Bayden J McKenzie" name="citation_author"/> <meta content="Cabrini Health" name="citation_author_institution"/> <meta content="bayden.mckenzie@monash.edu" name="citation_author_email"/> <meta content="Mihir D Wechalekar" name="citation_author"/> <meta content="Repatriation General Hospital" name="citation_author_institution"/> <meta content="Renea V Johnston" name="citation_author"/> <meta content="Cabrini Health" name="citation_author_institution"/> <meta content="Naomi Schlesinger" name="citation_author"/> <meta content="Rutgers - Robert Wood Johnson Medical School" name="citation_author_institution"/> <meta content="Rachelle Buchbinder" name="citation_author"/> <meta content="Cabrini Health" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD006190.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/08/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006190.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006190.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006190.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Inflammatory Agents, Non-Steroidal [adverse effects]; *Colchicine [adverse effects]; Glucocorticoids [therapeutic use]; *Gout [drug therapy]; Pain [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006190.pub3&amp;doi=10.1002/14651858.CD006190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="18M35a5z";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006190\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006190\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ko","pt","ms","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006190.pub3",title:"Colchicine for acute gout",firstPublishedDate:"Aug 26, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006190.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006190.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006190.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006190.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006190.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006190.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006190.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006190.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006190.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006190.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10052 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006190.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-sec-0068"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-sec-0062"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/appendices#CD006190-sec-0073"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/table_n/CD006190StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/table_n/CD006190StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Colchicine for acute gout</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/information#CD006190-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Bayden J McKenzie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/information#CD006190-cr-0005">Mihir D Wechalekar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/information#CD006190-cr-0006">Renea V Johnston</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/information#CD006190-cr-0007">Naomi Schlesinger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006190.pub3/information#CD006190-cr-0008">Rachelle Buchbinder</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/information/en#CD006190-sec-0080">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 August 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006190.pub3">https://doi.org/10.1002/14651858.CD006190.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006190-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006190-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006190-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006190-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006190-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006190-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006190-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006190-abs-0001" lang="en"> <section id="CD006190-sec-0001"> <h3 class="title" id="CD006190-sec-0001">Background</h3> <p>This is an updated Cochrane Review, first published in 2006 and updated in 2014. Gout is one of the most common rheumatic diseases worldwide. Despite the use of colchicine as one of the first‐line therapies for the treatment of acute gout, evidence for its benefits and harms is relatively limited. </p> </section> <section id="CD006190-sec-0002"> <h3 class="title" id="CD006190-sec-0002">Objectives</h3> <p>To update the available evidence of the benefits and harms of colchicine for the treatment of acute gout. </p> </section> <section id="CD006190-sec-0003"> <h3 class="title" id="CD006190-sec-0003">Search methods</h3> <p>We updated the search of CENTRAL, MEDLINE, Embase, Clinicaltrials.gov and WHO ICTRP registries to 28 August 2020. We did not impose any date or language restrictions in the search. </p> </section> <section id="CD006190-sec-0004"> <h3 class="title" id="CD006190-sec-0004">Selection criteria</h3> <p>We considered published randomised controlled trials (RCTs) and quasi‐randomised controlled trials (quasi‐RCTs) evaluating colchicine therapy compared with another therapy (placebo or active) in acute gout; low‐dose colchicine at clinically relevant doses compared with placebo was the primary comparison. The major outcomes were pain, participant global assessment of treatment success (proportion with 50% or greater decrease in pain from baseline up to 32 to 36 hours), reduction of inflammation, function of target joint, serious adverse events, total adverse events and withdrawals due to adverse events. </p> </section> <section id="CD006190-sec-0005"> <h3 class="title" id="CD006190-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures as expected by Cochrane in this review update. </p> </section> <section id="CD006190-sec-0006"> <h3 class="title" id="CD006190-sec-0006">Main results</h3> <p>We included four trials (803 randomised participants), including two new trials, in this updated review. One three‐arm trial compared high‐dose colchicine (52 participants), low‐dose colchicine (74 participants) and placebo (59 participants); one trial compared high‐dose colchicine with placebo (43 participants); one trial compared low‐dose colchicine with non‐steroidal anti‐inflammatory drugs (NSAIDs) (399 participants); and one trial compared low‐dose colchicine with Chuanhu anti‐gout mixture (traditional Chinese Medicine compound) (176 participants). We did not identify any trials comparing colchicine to glucocorticoids (by any route). </p> <p>The mean age of participants ranged from 51.2 to 70 years, and trial duration from 48 hours to 12 weeks. Two trials were at low risk of bias, one was possibly susceptible to selection bias (random sequence generation), reporting bias and other bias, and one open‐label trial was at high risk of performance and detection bias. </p> <p>For the primary comparison, low‐quality evidence from one trial (103 participants, downgraded for imprecision and bias) suggests low‐dose colchicine may improve treatment outcome compared to placebo with little or no increased risk of adverse events. The number of people who reported treatment success (50% or greater pain reduction) at 32 to 36 hours was slightly larger with low‐dose colchicine (418 per 1000) compared with placebo (172 per 1000; risk ratio (RR) 2.43, 95% confidence interval (CI) 1.05 to 5.64; absolute improvement 25% more reported success (7% more to 42% more, the 95% CIs include both a clinically important and unimportant benefit); relative change of 143% more people reported treatment success (5% more to 464% more). The incidence of total adverse events was 364 per 1000 with low‐dose colchicine compared with 276 per 1000 with placebo: RR 1.32, 95% CI 0.68 to 2.56; absolute difference 9% more events with low‐dose colchicine (9% fewer to 43% more, the 95% CIs include both a clinically important effect and no effect); relative change of 32% more events (32% fewer to 156% more). No participants withdrew due to adverse events or reported any serious adverse events. Pain, inflammation and function were not reported. </p> <p>Low‐quality evidence (downgraded for imprecision and bias) from two trials (124 participants) suggests that high‐dose colchicine compared to placebo may improve symptoms, but with increased risk of harms. More participants reported treatment success at 32 to 36 hours with high‐dose colchicine (518 per 1000) compared with placebo (240 per 1000): RR 2.16, 95% CI 1.28 to 3.65, absolute improvement 28% (8% more to 46% more); more also had reduced inflammation at this time point with high‐dose colchicine (504 per 1000) compared with placebo (48 per 1000): RR 10.50, 95% CI 1.48 to 74.38; absolute improvement 45% greater (22% greater to 68% greater); but more adverse events were reported with high‐dose colchicine (829 per 1000 compared with 260 per 1000): RR 3.21, 95% CI 2.01 to 5.11, absolute difference 57% (26% more to 74% more). Pain and function were not reported. </p> <p>Low‐quality evidence from a single trial comparing high‐dose to low‐dose colchicine indicates there may be little or no difference in benefit in terms of treatment success at 32 to 36 hours but more adverse events associated with the higher dose. Similarly, low‐quality evidence from a single trial indicates there may also be little or no benefit of low‐dose colchicine over NSAIDs in terms of treatment success and pain reduction at seven days, with a similar number of adverse events reported at four weeks follow‐up. Reduction of inflammation, function of target joint and withdrawals due to adverse events were not reported in either of these trials, and pain was not reported in the high‐dose versus low‐dose colchicine trial. </p> <p>We were unable to estimate the risk of serious adverse events for most comparisons as there were few events reported in the trials. One trial (399 participants) reported three serious adverse (one in a participant receiving low‐dose colchicine and two in participants receiving NSAIDs), due to reasons unrelated to the trial (low‐quality evidence downgraded for bias and imprecision). </p> </section> <section id="CD006190-sec-0007"> <h3 class="title" id="CD006190-sec-0007">Authors' conclusions</h3> <p>We found low‐quality evidence that low‐dose colchicine may be an effective treatment for acute gout when compared to placebo and low‐quality evidence that its benefits may be similar to NSAIDs. We downgraded the evidence for bias and imprecision. While both high‐ and low‐dose colchicine improve pain when compared to placebo, low‐quality evidence suggests that high‐dose (but not low‐dose) colchicine may increase the number of adverse events compared to placebo, while low‐quality evidence indicates that the number of adverse events may be similar with low‐dose colchicine and NSAIDs. </p> <p>Further trials comparing colchicine to placebo or other treatment will likely have an important impact on our confidence in the effect estimates and may change the conclusions of this review. There are no trials reporting the effect of colchicine in populations with comorbidities or in comparison with other commonly used treatments, such as glucocorticoids. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006190-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006190-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006190-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006190-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006190-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006190-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006190-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006190-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006190-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006190-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006190-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006190-abs-0002" lang="en"> <h3>Colchicine for treating acute gout flares</h3> <p><b>Background</b> </p> <p>Gout is a very common cause of inflammatory arthritis (pain, redness, warmth and swelling of affected joints) and is caused by urate crystals forming either within or around joints. Uric acid is a normal waste product that is usually excreted with urine. However, in the case of gout, there is either excessive production of uric acid, or the body is not able to excrete it quickly enough, or a combination of both. An attack of gout usually occurs rapidly and usually resolves within 7 to 10 days. </p> <p>Colchicine is a drug that is used mainly in gout to treat an acute attack or to prevent an attack while starting uric acid‐lowering therapy. </p> <p><b>Study characteristics</b> </p> <p>This Cochrane Review is current to August 2020. We included four trials (803 randomised participants) in this updated review, including two new trials. One three‐arm trial compared high‐dose colchicine (52 participants), low‐dose colchicine (74 participants) and placebo (fake medicine) (59 participants); one trial compared high‐dose colchicine with placebo (43 participants); one trial compared low‐dose colchicine with non‐steroidal anti‐inflammatory drugs (NSAIDs) (399 participants); and one trial compared low‐dose colchicine with Chuanhu anti‐gout mixture (traditional Chinese Medicine compound) (176 participants). We selected low‐dose colchicine compared with placebo as the primary comparison; the low dose is consistent with doses used in practice. Trials were performed in hospital and multicentre settings in four countries, the majority of participants were male, and mean age ranged between 51.2 and 70 years. One trial received funding from a pharmaceutical company that was involved in the study design, data collection, data analysis, and manuscript writing. </p> <p><b>Key results</b> </p> <p>Compared with placebo medication, low‐dose colchicine for people with acute gout may slightly improve treatment outcomes with little or no increased risk of adverse events at 32 to 36 hours. </p> <p><i>Proportion of participants reporting treatment success (defined as 50% or more reduction in pain)</i> </p> <p>25% more people (7% more to 42% more) reported success, or 25 more out of 100</p> <p>‐ 42 people out of 100 reported treatment success with colchicine</p> <p>‐ 17 people out of 100 reported treatment success with placebo</p> <p><i>Total adverse events (diarrhoea, vomiting or nausea)</i> </p> <p>6% more people reported adverse events (13% more to 23% more), or 6 more out of 100</p> <p>‐ 26 people out of 100 reported side effects with colchicine</p> <p>‐ 20 people out of 100 reported side effects with placebo</p> <p>Pain, reduction of inflammation, function of target joint, serious adverse events or withdrawals due to adverse events were not reported for this comparison. </p> <p>Other comparisons are briefly summarised here:</p> <p>High‐dose colchicine may improve symptoms compared with placebo, but with more adverse events. High‐dose may have little or no benefit over low‐dose colchicine but more adverse events. There may also be little or no benefit of low‐dose colchicine over NSAIDs in terms of treatment success and pain reduction, with a similar number of adverse events. </p> <p>There were no trials that compared colchicine to glucocorticoids.</p> <p><b>Quality of the evidence</b> </p> <p>We found low‐quality evidence that low‐dose colchicine may be an effective treatment for acute gout when compared to placebo and low‐quality evidence that its benefits may be similar to NSAIDs. We downgraded the evidence for bias and imprecision. While both high‐ and low‐dose colchicine improve treatment success when compared to placebo, high‐dose (but not low‐dose) colchicine may increase the number of adverse events compared to placebo while the number of adverse events may be similar with low‐dose colchicine compared with NSAIDs. </p> <p>Further research is very likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006190-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006190-sec-0068"></div> <h3 class="title" id="CD006190-sec-0069">Implications for practice</h3> <section id="CD006190-sec-0069"> <p>Based upon only four published trials, two with a low risk of bias, one with an unclear risk of bias and one with a high risk of bias, there is low‐quality evidence that low‐dose colchicine may be an effective treatment for acute gout. We downgraded the evidence because of a potential risk of selection and reporting biases, the high risk of performance and detection bias in one open‐label trial, and the small number of trial participants and the low event rates indicating imprecision. Both high‐ and low‐dose colchicine improve pain when compared to placebo, however, low‐dose colchicine may be the preferred treatment option for acute gout as low‐quality evidence suggests that high‐dose (but not low‐dose) colchicine may increase the number of adverse events compared to placebo. </p> <p>From a clinical perspective, first‐line treatment of acute gout is a choice between low‐dose colchicine, NSAIDs or glucocorticoids, and guidelines do not differentiate between them except to note that a patient's risk profile and comorbidities will likely influence the choice of therapy in clinical practice. New data presented in this review indicates that there may be no difference in efficacy between low‐dose colchicine and NSAIDs. </p> </section> <h3 class="title" id="CD006190-sec-0070">Implications for research</h3> <section id="CD006190-sec-0070"> <p>RCTs comparing low‐dose colchicine to glucocorticoids may further benefit clinical decision‐making. Such studies should ideally be pragmatic in the way that they include people with gout and all their typical comorbidities. </p> <p>Planned trials should include participants with a range of gout manifestations (e.g. tophi, nephrolithiasis), comorbidities that influence pharmacotherapy choice for gout treatment (e.g. renal impairment, cardiovascular disease) and assess the outcomes recommended by OMERACT for studies of acute gout, including a reduction in gout flare frequency, joint pain, serum urate concentration, tophus burden, physical function and quality of life (<a href="./references#CD006190-bbs2-0059" title="SinghJA , TaylorWJ , SimonLS , KhannaPP , StampLK , McQueenFM , et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. Journal of Rheumatology2011;38:1452-7.">Singh 2011</a>). The CONSORT statement should also be used to guide both designing and reporting studies (<a href="./references#CD006190-bbs2-0025" title="BoutronI , MoherD , AltmanDG , SchulzK , RavaudP , CONSORT Group. Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments. Annals of Internal Medicine2008;148:295-309.">Boutron 2008</a>). </p> <p>Trial reporting should include the method of randomisation and treatment allocation concealment, blinding of trial participants, trial personnel and outcome assessment, follow‐up of all participants who entered the trial and complete reporting of outcomes. Sample sizes should be reported and have adequate power to answer the research question; ideally trials should assess both the benefits and risks of lifestyle interventions. To enable comparison and pooling of the results of RCTs, we suggest that future trials report means with standard deviations (SDs) for continuous measures or number of events and total numbers analysed for dichotomous measures, and use standardised measurement tools for reporting relevant outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006190-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006190-sec-0008"></div> <div class="table" id="CD006190-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Low‐dose colchicine versus placebo for acute gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Low‐dose colchicine versus placebo for acute gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with acute gout<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> low‐dose colchicine versus placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control (placebo)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Low‐dose colchicine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant global assessment of treatment success:</b> proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>418 per 1000</b><br/>(181 to 970) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b> <br/>(1.05 to 5.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose colchicine may slightly increase the number of people who report treatment success. </p> <p>Absolute difference: 25% more reported success (7% more to 42% more);</p> <p>relative percentage change: 143% (5% more to 464% more)</p> <p>NNTB 5 (2 to 39)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of inflammation</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function of target joint</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants reported no serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>276 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b><br/>(188 to 706) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> <br/>(0.68 to 2.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose colchicine may have little or no effect on the number of people reporting adverse events. </p> <p>Absolute difference: 9% more events with low‐dose colchicine (11% fewer to 29% more), compared to placebo. </p> <p>Relative percentage change: 32% more events (32% fewer to 156% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participants withdrew due to adverse events in either study arm.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB</b> : number needed to treat for an additional beneficial outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to a risk of selection bias from unclear reporting of the method of randomisation, and a risk of reporting bias.<br/><sup>b</sup>Downgraded one level for imprecision as the number of events was small (&lt; 200) and 95% CI includes no effect, or appreciable benefit.<br/><sup>c</sup>Note: number needed to treat for an additional beneficial (NNTB) or harmful outcome (NNTH) is not reported when result is not statistically significant. Number needed to treat for dichotomous outcomes calculated using 1/risk difference for single studies and Cates NNT calculator for meta‐analyses (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006190-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">High‐dose colchicine versus placebo for acute gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>High‐dose colchicine versus placebo for acute gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with acute gout<br/><b>Settings:</b> hospital and outpatient<br/><b>Intervention:</b> high‐dose colchicine versus placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control (Placebo)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>High‐dose colchicine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant global assessment of treatment success:</b> proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>518 per 1000</b><br/>(307 to 876) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.16</b> <br/>(1.28 to 3.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose colchicine may increase the number of people reporting treatment success.</p> <p>Absolute difference: 28% more reported success (8% more to 46% more);</p> <p>relative percentage change: 116% (28% more to 265% more).</p> <p>NNTB: 4 (3 to 12)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of inflammation:</b> proportion with 50% or greater decrease in inflammation score from baseline ‐ 32 to 36 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>504 per 1000</b><br/>(278 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 10.50</b> (1.48 to 74.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose colchicine may increase the number of people with reduced inflammation.</p> <p>Absolute difference: 45% greater reduction of inflammation with colchicine (22% greater to 68% greater). </p> <p>Relative percentage change: 950% (48% more to 7338% more)</p> <p>NNTB: 3 (2 to 19)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function of target joint</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported that there were no serious adverse events and one study did not report whether any serious adverse events occurred or not. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>829 per 1000</b><br/>(520 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.21</b> <br/>(2.01 to 5.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose colchicine may increase the number of people reporting adverse events.</p> <p>Absolute difference: 57% more events with high‐dose colchicine (26% more to 74% more), compared to placebo. </p> <p>Relative percentage change: 221% (101% more to 411% more).</p> <p>NNTH: 2 (2 to 10)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported that there were no withdrawals due to adverse events and one study did not report whether withdrawals due to adverse events occurred or not. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB</b> : number needed to treat for an additional beneficial outcome; <b>NNTH</b> : number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to a risk of selection bias from unclear reporting of the method of randomisation, and a risk of reporting bias in one study.<br/><sup>b</sup>Downgraded one level for imprecision as the total number of participants is small and the total number of events is small.<br/><sup>c</sup>Note: number needed to treat for an additional beneficial (NNTB) or harmful outcome (NNTH) is reported when the difference between treatment and control is statistically significant, calculated using Cates NNT calculator for dichotomous outcomes (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006190-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High‐dose versus low‐dose colchicine for acute gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>High‐dose versus low‐dose colchicine for acute gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with acute gout<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> high‐dose versus low‐dose colchicine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control (low‐dose colchicine)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>High‐dose colchicine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant global assessment of treatment success:</b> proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>419 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b><br/>(235 to 570) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> <br/>(0.56 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests little to no difference for the proportion of people reporting treatment success between high‐dose colchicine and low‐dose colchicine. </p> <p>Absolute difference: 5% fewer reported success (23% fewer to 12% more).</p> <p>Relative percentage change: 13% fewer (44% fewer to 136% more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of inflammation</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function of target joint</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported that there were no serious adverse events in either study arm.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>770 per 1000</b><br/>(551 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.11</b> <br/>(1.51 to 2.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose colchicine may increase the number of adverse events compared to low‐dose colchicine. </p> <p>Absolute difference: 41% more events with high‐dose (19% more to 71% more), compared to low‐dose colchicine. </p> <p>Relative percentage change: 111% more events (51% more to 195% more).</p> <p>NNTH: 3 (2 to 5)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported that there were no withdrawals due to adverse events in either study arm. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTH</b> : number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to a risk of selection bias from unclear reporting of the method of randomisation, and a risk of reporting bias.<br/><sup>b</sup>Downgraded one level for imprecision as the number of events was small (&lt; 200) and 95% CI includes no effect, or appreciable benefit.<br/><sup>c</sup>Note: number needed to treat for an additional beneficial (NNTB) or harmful outcome (NNTH) is reported when the difference between treatment and control is statistically significant, calculated using Cates NNT calculator for dichotomous outcomes (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006190-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Low‐dose colchicine versus NSAIDs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Low‐dose colchicine versus NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with acute gout<br/><b>Settings:</b> 100 GPs across England<br/><b>Intervention:</b> low‐dose colchicine versus naproxen </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control (NSAIDs)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Low‐dose colchicine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>NRS Scale from 0 to 10, 0 is no pain.</p> <p>Follow‐up: 7 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain was 0.1 points worse (0.29 better to 0.49 worse)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>399</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose colchicine may have little or no effect on pain when compared to NSAIDs.</p> <p>Absolute difference: 1% worse pain (3% better to 5% worse).</p> <p>Relative percentage change: 1.4% worse (4% better to 7% worse)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant global assessment of treatment success:</b> </p> <p>Completely better/much better</p> <p>Follow‐up: 7 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>570 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>553 per 1000</b><br/>(467 to 655) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b><br/>(0.82 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>399</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose colchicine may have little or no effect on the number of people reporting treatment success. </p> <p>Absolute difference: 1.7% fewer people reported treatment success as completely better or much better with low‐dose colchicine (10.3% fewer to 8.5% more), compared to NSAIDs. Relative percentage change: 3% fewer (18% fewer to 15% more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of inflammation</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function of target joint</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were three serious adverse events (2 from the NSAIDs group and 1 from low‐dose colchicine group), none related to study interventions, and no deaths. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants reporting adverse events</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>535 per 1000</b><br/>(440 to 645) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b><br/>(0.88 to 1.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>399</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose colchicine may have little or no difference to the number of adverse events compared to NSAIDs. </p> <p>Absolute difference: 3.5% more people reported adverse events (6% fewer to 14.5% more), compared to NSAIDs. Relative percentage change: 7% (12% fewer to 29% more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was one withdrawal from the low‐dose colchicine group with the reason unreported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>GPs</b> : general practices; <b>NRS</b> : numeric rating scale; <b>NSAIDs</b> : non‐steroidal anti‐inflammatory drugs; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to a risk of performance and detection bias.<br/><sup>b</sup>Downgraded one level for imprecision as the number of events was small (&lt; 200) and 95% CI includes no effect, or appreciable benefit. Data were from a single study only, which may have been inadequately powered to detect a clinically important change in pain between groups (defined as 1.5 points on the 0 to 10 NRS pain scale).<br/><sup>c</sup>Relative change was calculated as absolute change (mean difference) divided by mean at baseline in the NSAIDs group from <a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a> (mean NRS baseline value was 7.1). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006190-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006190-sec-0009"></div> <section id="CD006190-sec-0010"> <h3 class="title" id="CD006190-sec-0010">Description of the condition</h3> <p>Gout is a disease in which monosodium urate crystals form deposits in and around the joints, which may result in painful, swollen and tender joints or soft tissues and/or tophi. The onset of acute gout is often sudden and dramatic, often beginning at night, and characterised by severe pain (<a href="./references#CD006190-bbs2-0055" title="SchumacherHR , EdwardsLN , Perez-RuizF , BeckerM , ChenLX , FurstDE . Outcome measures for acute and chronic gout. Journal of Rheumatology2005;32(12):2452-5.">Schumacher 2005</a>). Uric acid is a normal waste product that is usually excreted from the body. However, in gout, there is either excessive production of uric acid (in a minority of people with gout) or the body is not able to excrete it quickly enough (in most people with gout), or both. This results in the formation of monosodium urate crystals. The lower extremity joints, particularly the first metatarsophalangeal joint, are most commonly affected. Other joints that can be affected include the ankle, knee, foot, hand, wrist and elbow. Usually, only one joint is affected (monoarthritis), but oligoarticular or polyarticular acute gout may also occur and is more prevalent in male hypertensive people and in postmenopausal women (<a href="./references#CD006190-bbs2-0044" title="KasperDL , BraunwaldE , FauciAS , HauserSL , LongoDL , JamesonDL , et al. Harrison's Principles of Internal Medicine. 16th edition. McGraw-Hill Professional, 2005.">Kasper 2005</a>). </p> <p>Gout is the most common form of inflammatory joint disease in men greater than 40 years of age. Its prevalence varies widely, since both genetic and environmental factors contribute to its incidence (<a href="./references#CD006190-bbs2-0055" title="SchumacherHR , EdwardsLN , Perez-RuizF , BeckerM , ChenLX , FurstDE . Outcome measures for acute and chronic gout. Journal of Rheumatology2005;32(12):2452-5.">Schumacher 2005</a>). The highest prevalence is among older men, with rates as high as 7% in men over the age of 65 years (<a href="./references#CD006190-bbs2-0046" title="MikulsTR , FarrarJT , FernandesS , Schumacher HR Jr, SaagKG . Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Annals of the Rheumatic Diseases2005;64:267-72.">Mikuls 2005</a>). Risk factors traditionally associated with gout include obesity, alcohol consumption, renal dysfunction, diuretic use and hyperuricaemia (<a href="./references#CD006190-bbs2-0068" title="WortmannRL . Gout and hyperuricemia. Current Opinion in Rheumatology2002;14:281-6.">Wortmann 2002</a>). Gout is historically perceived as a disease afflicting men, while women represent only 5% to 17% of all people with the disease. Premenopausal gout is rare and seen mostly in women with strong family histories of the disorder (<a href="./references#CD006190-bbs2-0044" title="KasperDL , BraunwaldE , FauciAS , HauserSL , LongoDL , JamesonDL , et al. Harrison's Principles of Internal Medicine. 16th edition. McGraw-Hill Professional, 2005.">Kasper 2005</a>). Menopause increases the risk of gout among women, whereas postmenopausal hormone therapy modestly reduces gout risk (<a href="./references#CD006190-bbs2-0036" title="HakAE , CurhanGC , GrodsteinF , ChoiHK . Menopause, postmenopausal hormone use and risk of incident gout. Annals of the Rheumatic Diseases2010;69(7):1305-9.">Hak 2010</a>). Some people recover from an acute gout flare without intervention within seven days, but the clinically significant pain associated with acute gout flares creates a need for agents that accelerate the rate of improvement (<a href="./references#CD006190-bbs2-0023" title="BellamyN , DownieWW , BuchananWW . Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology1987;24(1):33-6.">Bellamy 1987</a>). </p> <p>Resting the afflicted joint for one to two days may aid in the resolution of a flare, and less medication may be needed to bring about the resolution (<a href="./references#CD006190-bbs2-0019" title="AgudeloCA , Schumacher HR Jr, PhelpsP . Effect of exercise on urate crystal-induced inflammation in canine joints. Arthritis and Rheumatism1972;15:609-16.">Agudelo 1972</a>; <a href="./references#CD006190-bbs2-0055" title="SchumacherHR , EdwardsLN , Perez-RuizF , BeckerM , ChenLX , FurstDE . Outcome measures for acute and chronic gout. Journal of Rheumatology2005;32(12):2452-5.">Schumacher 2005</a>). Ice therapy has been suggested to reduce the pain associated with acute flares; cold application may be a useful adjunct to the pharmacological treatment of acute gout (<a href="./references#CD006190-bbs2-0047" title="MoiJH , SriranganathanMK , EdwardsCJ , BuchbinderR . Lifestyle interventions for chronic gout. Cochrane Database of Systematic Reviews2013, Issue 5. Art. No: CD010039. [DOI: 10.1002/14651858.CD010039.pub2]">Moi 2013</a>; <a href="./references#CD006190-bbs2-0013" title="SchlesingerN , BakerDG , BeutlerAM , HoffmanBI , Schumacher Hr Jr. Local ice therapy during bouts of acute gouty arthritis. Journal of Rheumatology2002;29(2):331-4. ">Schlesinger 2002</a>). Heat application to an inflamed joint may exacerbate inflammation and is not recommended (<a href="./references#CD006190-bbs2-0032" title="DorwartBB , HansellJR , Schumacher HR Jr. Effects of cold and heat on urate-induced synovitis in the dog. Arthritis and Rheumatism1974;17(5):563-71.">Dorwart 1974</a>). Avoidance of triggers such as alcohol may reduce the frequency of flares (<a href="./references#CD006190-bbs2-0063" title="TugwellP , SheaB , BoersM , BrooksP , SimonLS , StrandV , et al. Evidence-Based Rheumatology. BMJ Books, 2004.">Tugwell 2004</a>). Dietary interventions, such as limitation of carbohydrate intake, and increased proportional intake of protein and the use of unsaturated fat, may also limit the frequency of acute gout flares (<a href="./references#CD006190-bbs2-0063" title="TugwellP , SheaB , BoersM , BrooksP , SimonLS , StrandV , et al. Evidence-Based Rheumatology. BMJ Books, 2004.">Tugwell 2004</a>). Pharmacological treatments that are commonly used in the treatment of acute gouty flares include oral non‐steroidal anti‐inflammatory drugs (NSAIDs), colchicine, oral glucocorticoids and injection of glucocorticoids into the affected joint (<a href="./references#CD006190-bbs2-0021" title="ArnoldMH , PrestonSJ , BuchananWW . Comparison of the natural history of untreated acute gouty arthritis vs acute gouty arthritis treated with non-steroidal-anti-inflammatory drugs. British Journal of Clinical Pharmacology1988;26:488-9.">Arnold 1988</a>; <a href="./references#CD006190-bbs2-0042" title="JanssensHJ , JanssenM , Van de LisdonkEH , Van RielPL , Van WeelC . Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet2008;371:1854-60.">Janssens 2008a</a>; <a href="./references#CD006190-bbs2-0043" title="JanssensHJ , LucassenPL , Van de LaarFA , JanssenM , Van de LisdonkEH . Systemic corticosteroids for acute gout. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: CD005521. [DOI: 10.1002/14651858.CD005521.pub2]">Janssens 2008b</a>; <a href="./references#CD006190-bbs2-0053" title="SchlesingerN . Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs2004;64(21):2399-416.">Schlesinger 2004</a>; <a href="./references#CD006190-bbs2-0066" title="WallaceSL , SingerJZ . Therapy in gout. Rheumatic Diseases Clinics of North America1988;14:441-57.">Wallace 1998</a>; <a href="./references#CD006190-bbs2-0067" title="WechalekarMD , VinikO , SchlesingerN , BuchbinderR . Intra-articular glucocorticoids for acute gout. Cochrane Database of Systematic Reviews2013, Issue 4. Art. No: CD009920. [DOI: 10.1002/14651858.CD009920.pub2]">Wechalekar 2013</a>). The use of adrenocorticotropic hormone may also aid in the resolution of acute gout flares (<a href="./references#CD006190-bbs2-0052" title="SchlesingerN , Schumacher HR Jr. Gout: can management be improved?Current Opinion in Rheumatology2001;13(3):240-4.">Schlesinger 2001</a>). In this review we focus on the evidence for colchicine in the treatment of acute gout. </p> </section> <section id="CD006190-sec-0011"> <h3 class="title" id="CD006190-sec-0011">Description of the intervention</h3> <p>In gout, monosodium urate crystals are phagocytosed and additional leucocytes are attracted to the site of inflammation. Colchicine is the main alkaloid of the poisonous autumn crocus plant and has been used to treat acute gout for over 2000 years (<a href="./references#CD006190-bbs2-0053" title="SchlesingerN . Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs2004;64(21):2399-416.">Schlesinger 2004</a>). </p> <p>Colchicine is available in oral and intravenous forms. The absorption of oral colchicine is rapid but can be highly variable. Relief of pain usually occurs 24 hours after colchicine is given orally (<a href="./references#CD006190-bbs2-0053" title="SchlesingerN . Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs2004;64(21):2399-416.">Schlesinger 2004</a>). </p> <p>Serious systemic reactions, including bone marrow suppression, renal failure, alopecia, disseminated intravascular coagulation, hepatic necrosis, diarrhoea, seizures and death, have all been associated with intravenous colchicine (<a href="./references#CD006190-bbs2-0066" title="WallaceSL , SingerJZ . Therapy in gout. Rheumatic Diseases Clinics of North America1988;14:441-57.">Wallace 1998</a>). </p> <p>The most common side effects of oral colchicine are nausea, vomiting and diarrhoea. These may be particularly difficult to endure when people are in pain and incapacitated by acute gouty arthritis (<a href="./references#CD006190-bbs2-0048" title="MorrisI , VarugheseG , MattinglyP . Colchicine in acute gout. BMJ2003;327(7426):1275-6.">Morris 2003</a>). </p> <p>The recommended dosage of oral colchicine has been debated in the literature, and the optimal dose is not well defined (<a href="./references#CD006190-bbs2-0028" title="CoxAR . Colchicine in acute gout: optimal dose of colchicine is still elusive. BMJ2004;328(7434):288.">Cox 2004</a>; <a href="./references#CD006190-bbs2-0048" title="MorrisI , VarugheseG , MattinglyP . Colchicine in acute gout. BMJ2003;327(7426):1275-6.">Morris 2003</a>; <a href="./references#CD006190-bbs2-0061" title="SivagnanamG . Colchicine in acute gout: low dose colchicine was started after usual dose. BMJ2004;328(7434):288-9.">Sivagnanam 2004</a>). International guidelines recommend using a low‐dose colchicine regimen because of the harms of higher doses, but vary in their specification of what the low‐dose regimen entails. The 2020 American College of Rheumatology recommends the US Food and Drug Administration (FDA) approved dosing of 1.2 mg immediately followed by 0.6 mg an hour later, with ongoing anti‐inflammatory therapy until the flare resolves (<a href="./references#CD006190-bbs2-0034" title="FitzGeraldJD , DalbethN , MikulsT , Brignardello-PetersenR , GuyattG , AbelesAM , et al. 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Care Research2020;0(0):1-17.">FitzGerald 2020</a>). The updated 2016 European League Against Rheumatism (EULAR) guidelines also recommend a loading dose of 1 mg (within 12 hours of flare onset) followed 1 hour later by 0.5 mg on day 1 along with or without an NSAID (<a href="./references#CD006190-bbs2-0051" title="RichetteP , DohertyM , PascualE , BarskovaV , BecceF , Castañeda-SanabriaJ , et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases2017;76:29-42.">Richette 2017</a>). The British Society of Rheumatology recommends 0.5 mg twice to four times daily, noting that the higher dose is often precluded by gastrointestinal side effects, most commonly diarrhoea (<a href="./references#CD006190-bbs2-0041" title="HuiM , CarrA , CameronS , DavenportG , DohertyM , ForresterH , et al, British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology Guideline for the management of gout. Rheumatology2017;56:e1-e20.">Hui 2017</a>). The Australian Rheumatology Association recommends 0.5 mg to 1 mg initially, followed by 0.5 mg one hour later and waiting 12 hours before taking the next 0.5 mg dose (<a href="./references#CD006190-bbs2-0022" title="Australian Rheumatology Association. Patient information on colchicine (last updated April 2019). rheumatology.org.au/patients/documents/Colchicine_2019v2.pdf (accessed 16 November 2020).">Australian Rheumatology Association 2019</a>). Thereafter, 0.5 mg to 1 mg can be taken daily for a couple of days to completely settle the flare. Multinational recommendations from 14 countries from Europe, North and South America and Australasia published in 2014, also recommended up to 2 mg daily of colchicine (<a href="./references#CD006190-bbs2-0064" title="SiveraF , AndrésM , CarmonaL , KyddAS , MoiJ , SethR , et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of abroad panel of rheumatologists in the 3e initiative. Annals of the Rheumatic Diseases2014;73:328–35.">van der Heijde 2014</a>). </p> <p>The guidelines also indicate that a reduced dose is recommended for people with renal impairment (e.g. estimated glomerular filtration rate (eGFR) 10 mL/min/1.73 m<sup>2</sup> to50 mL/min/1.73 m<sup>2</sup>) and the elderly, and avoidance in people with more severe renal impairment (GFR &lt; 10 mL/min/1.73 m<sup>2</sup>). It should also be used with caution and at low doses in people taking potent inhibitors of cytochrome P450 3A4 (e.g. cimetidine, clarithromycin, erythromycin, fluoxetine, ketoconazole, protease inhibitors, tolbutamide) or P‐glycoprotein (e.g. clarithromycin, ciclosporin, erythromycin). Some also advise caution when using colchicine in people receiving statins, particularly in those with renal impairment, as there are case reports of myopathy and rhabdomyolysis following their combined use (<a href="./references#CD006190-bbs2-0041" title="HuiM , CarrA , CameronS , DavenportG , DohertyM , ForresterH , et al, British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology Guideline for the management of gout. Rheumatology2017;56:e1-e20.">Hui 2017</a>; <a href="./references#CD006190-bbs2-0051" title="RichetteP , DohertyM , PascualE , BarskovaV , BecceF , Castañeda-SanabriaJ , et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases2017;76:29-42.">Richette 2017</a>). </p> </section> <section id="CD006190-sec-0012"> <h3 class="title" id="CD006190-sec-0012">How the intervention might work</h3> <p>The exact mechanism by which colchicine relieves the pain of an acute flare is not presently known. The major pharmacological action of colchicine is its ability to bind to tubulin dimers (<a href="./references#CD006190-bbs2-0053" title="SchlesingerN . Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs2004;64(21):2399-416.">Schlesinger 2004</a>). It prevents the polymerisation of microtubules by binding their protein subunits and preventing conglomeration, thereby disrupting membrane‐dependent functions, such as chemotaxis and phagocytosis (<a href="./references#CD006190-bbs2-0054" title="SchumacherH , KlippelJ , KoopmanW . Primer on the Rheumatic Diseases. 10th edition. Arthritis Foundation, 1993.">Schumacher 1993</a>). Colchicine is also suspected to interfere with leukocyte function, preventing diapedesis, mobilisation, lysosomal degranulation and chemotaxis (<a href="./references#CD006190-bbs2-0053" title="SchlesingerN . Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs2004;64(21):2399-416.">Schlesinger 2004</a>). </p> </section> <section id="CD006190-sec-0013"> <h3 class="title" id="CD006190-sec-0013">Why it is important to do this review</h3> <p>The natural course of untreated gouty arthritis flares can last from several hours to several weeks (<a href="./references#CD006190-bbs2-0053" title="SchlesingerN . Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs2004;64(21):2399-416.">Schlesinger 2004</a>). Although resting the affected joint and cold therapy may provide some relief of symptoms, non‐pharmacological measures often fall short (<a href="./references#CD006190-bbs2-0019" title="AgudeloCA , Schumacher HR Jr, PhelpsP . Effect of exercise on urate crystal-induced inflammation in canine joints. Arthritis and Rheumatism1972;15:609-16.">Agudelo 1972</a>; <a href="./references#CD006190-bbs2-0047" title="MoiJH , SriranganathanMK , EdwardsCJ , BuchbinderR . Lifestyle interventions for chronic gout. Cochrane Database of Systematic Reviews2013, Issue 5. Art. No: CD010039. [DOI: 10.1002/14651858.CD010039.pub2]">Moi 2013</a>; <a href="./references#CD006190-bbs2-0013" title="SchlesingerN , BakerDG , BeutlerAM , HoffmanBI , Schumacher Hr Jr. Local ice therapy during bouts of acute gouty arthritis. Journal of Rheumatology2002;29(2):331-4. ">Schlesinger 2002</a>). Therefore it is important to understand the benefits and harms of pharmacological agents. </p> <p>Colchicine is commonly used to treat people with mono‐ or oligoarticular acute gout but has potential side effects. In addition, people with gout may have clinically significant comorbidities that may influence the choice of therapy. While rheumatologic guidelines recommend using low‐dose oral colchicine to treat people with acute gout, the exact regimen varies between guidelines. This Cochrane Review was last updated in 2014. It is therefore timely to update it to include any relevant new evidence that may alter guidance about the use of colchicine for acute gout. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006190-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006190-sec-0014"></div> <p>To update the available evidence of the benefits and harms of colchicine for the treatment of acute gout. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006190-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006190-sec-0015"></div> <section id="CD006190-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006190-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included published randomised and quasi‐randomised controlled trials (RCTs or quasi‐RCTs).</p> </section> <section id="CD006190-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials that enrolled adults (aged 18 years or older) with a diagnosis of acute gout (author defined or presence of monosodium crystals in joint aspirate, or people fulfilling the American College of Rheumatology (<a href="./references#CD006190-bbs2-0065" title="WallaceSL , RobinsonH , MasiAT , DeckerJL , McCartyDJ , Yu T-F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis and Rheumatism1977;20:895-900.">Wallace 1977</a>), or the Rome (1963) or New York (1966) criteria for gout (<a href="./references#CD006190-bbs2-0049" title="O'SullivanJB . Gout in a New England Town. A prevalence study in Sudbury, Massachusetts. Annals of the Rheumatic Diseases1972;31(3):166-9.">O'Sullivan 1972</a>)). We excluded populations that included a mix of people with acute gout and other musculoskeletal pain unless results for the acute gout population could be separated out from the analysis. </p> </section> <section id="CD006190-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials that evaluated the benefits or harms (or both) of colchicine administered by any route and at any dose. </p> <p>We included any comparator, such as:</p> <p> <ul id="CD006190-list-0001"> <li> <p>placebo or no treatment;</p> </li> <li> <p>non‐steroidal anti‐inflammatory drugs (NSAIDs; via any route);</p> </li> <li> <p>glucocorticoids (via any route);</p> </li> <li> <p>other pharmacologic treatment (e.g. paracetamol);</p> </li> <li> <p>complementary and alternative medicines;</p> </li> <li> <p>one dose of colchicine versus another;</p> </li> <li> <p>combination therapy (any of the above combinations).</p> </li> </ul> </p> </section> <section id="CD006190-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>There is considerable variation in the outcome measures reported in trials of interventions for acute gout (<a href="./references#CD006190-bbs2-0020" title="AraújoF , CordeiroI , RamiroS , FalzonL , BrancoJC , BuchbinderR . Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review. Rheumatology2015;54(6):981-93.">Araújo 2015</a>). For the purpose of this review, we aimed to include outcome measures that are considered to be of greatest importance to patients with acute gout and the clinicians who care for them. </p> <p>OMERACT (Outcome Measures in Rheumatology Clinical Trials) has endorsed outcome measures to be used in evaluation of resolution of acute flares (<a href="./references#CD006190-bbs2-0029" title="DalbethN , ZhongCS , GraingerR , KhannaD , KhannaPP , SinghJA , et al. Outcome measures in acute gout: a systematic literature review. Journal of Rheumatology2014;41(3):558-68.">Dalbeth 2014</a>; <a href="./references#CD006190-bbs2-0060" title="SinghJA , TaylorWJ , DalbethN , SimonLS , SundyJ , GraingerR , et al. OMERACT endorsement of measures of outcome for studies of acute gout. Journal of Rheumatology2014;41(3):569-73.">Singh 2014</a>). Intense pain is the hallmark of an acute gout flare and hence pain has been endorsed by OMERACT as an outcome measure; it has also been a consistent outcome measure in trials involving acute gout flares, although the instruments and time intervals used to measure pain vary (<a href="./references#CD006190-bbs2-0020" title="AraújoF , CordeiroI , RamiroS , FalzonL , BrancoJC , BuchbinderR . Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review. Rheumatology2015;54(6):981-93.">Araújo 2015</a>). The additional outcome measures endorsed by OMERACT include joint swelling, joint tenderness and patient global assessment (<a href="./references#CD006190-bbs2-0060" title="SinghJA , TaylorWJ , DalbethN , SimonLS , SundyJ , GraingerR , et al. OMERACT endorsement of measures of outcome for studies of acute gout. Journal of Rheumatology2014;41(3):569-73.">Singh 2014</a>). </p> <section id="CD006190-sec-0021"> <h5 class="title">Major outcomes</h5> <p> <ul id="CD006190-list-0002"> <li> <p>Pain (mean or mean change from baseline), measured by visual analogue scales (VAS), numerical or categorical ratings scales or other scales </p> </li> <li> <p>Participant global assessment of treatment success, e.g. proportion reporting 50% or greater decrease in pain, completely improved, etc. </p> </li> <li> <p>Reduction of inflammation (e.g. proportion reporting a reduction in joint swelling/erythema/tenderness or categorical scales) </p> </li> <li> <p>Function of target joint (mean or mean change from baseline), measured by function scales </p> </li> <li> <p>Serious adverse events (proportion of participants reporting the event in each group)</p> </li> <li> <p>Total adverse events (proportion of participants reporting the event in each group)</p> </li> <li> <p>Withdrawals due to adverse events (proportion of participants reporting the event in each group) </p> </li> </ul> </p> </section> <section id="CD006190-sec-0022"> <h5 class="title">Minor outcome</h5> <p> <ul id="CD006190-list-0003"> <li> <p>Health‐related quality of life (mean or mean change from baseline), measured by generic quality of life scales such as SF‐36 </p> </li> </ul> </p> <p>We considered inclusion of all endpoints as measured in the included trials and combined data into short (up to 2 weeks), medium (2 to 6 weeks) and long‐term (more than 6 weeks). The primary time point for benefits was up to two weeks or the earliest time point if this time point was not reported. For harms the primary time point was end of trial. </p> </section> </section> </section> <section id="CD006190-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006190-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched a registry of all RCTs in gout, established by Cochrane Musculoskeletal to facilitate the updates of a series of reviews of interventions for gout, including this review update. </p> <p>The search for the gout registry was designed not to include terms for any interventions, in order to establish a registry of all randomised trials in this condition, regardless of the intervention. </p> <p>The following electronic databases were searched to establish the registry. The search strategy combined standard Cochrane search filters for 'gout' and 'randomised trial', with no language restrictions. </p> <p> <ul id="CD006190-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via OVID to 28 Aug 2020 (<a href="./appendices#CD006190-sec-0074">Appendix 1</a>). </p> </li> <li> <p>OVID MEDLINE 1948 to 28 Aug 2020 (<a href="./appendices#CD006190-sec-0075">Appendix 2</a>). </p> </li> <li> <p>Embase via OVID 1980 to 28 Aug 2020 (<a href="./appendices#CD006190-sec-0076">Appendix 3</a>). </p> </li> </ul> </p> <p>We also searched the clinical trials register <a href="https://clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a> and the World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="https://www.who.int/clinical-trials-registry-platform" target="_blank">WHO ICTRP</a>) for relevant trials using the search term, 'gout'. </p> <p>Details of the search strategies used for the previous version of the review are given in <a href="./references#CD006190-bbs2-0071" title="vanEchteldI , WechalekarMD , SchlesingerN , BuchbinderR , AletahaD . Colchicine for acute gout. Cochrane Database of Systematic Reviews2014, Issue 8. Art. No: CD006190. [DOI: 10.1002/14651858.CD006190.pub2]">van Echteld 2014</a>. </p> </section> <section id="CD006190-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We inspected the reference lists of included articles for potentially eligible additional trials. </p> </section> </section> <section id="CD006190-sec-0026"> <h3 class="title" id="CD006190-sec-0026">Data collection and analysis</h3> <section id="CD006190-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Editorial staff from Cochrane Musculoskeletal initially screened titles and abstracts in the gout registry and retrieved the full text for all records they identified as RCTs of an intervention for people with gout. </p> <p>Editorial staff annotated the population, intervention and comparator for each full‐text article, and assigned it to the appropriate gout review. </p> <p>Review authors (BM and RJ) imported these records into Covidence to select trials eligible for this review update (<a href="./references#CD006190-bbs2-0027" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, accessed 27 August 2020. Available at covidence.org.">Covidence 2021</a>). </p> </section> <section id="CD006190-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>One review author (BM) extracted data regarding trial design, trial duration, characteristics of trial population, interventions, co‐interventions, adverse effects and loss to follow‐up of included trials, using a standardised data extraction form, and another review author (RJ or RB) checked the extraction. Outcome data were extracted in duplicate by BM and RJ. We resolved differences in data extraction by referring back to the original articles and establishing consensus, disagreements were resolved with a third review author (RB). Outcomes for this review were updated from those specified in the protocol (see <a href="#CD006190-sec-0084">Differences between protocol and review</a>). </p> <section id="CD006190-sec-0029"> <h5 class="title">Comparisons</h5> <p>We included the following comparisons.</p> <p> <ul id="CD006190-list-0005"> <li> <p>Low‐dose colchicine versus placebo</p> </li> <li> <p>High‐dose colchicine versus placebo</p> </li> <li> <p>High‐dose versus low‐dose colchicine</p> </li> <li> <p>Colchicine versus NSAIDs</p> </li> <li> <p>Colchicine versus glucocorticoids</p> </li> </ul> </p> </section> </section> <section id="CD006190-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (BM and RJ) independently assessed the risk of bias of each included trial with regard to random sequence generation; allocation concealment; blinding of participants, care provider and outcome assessor for each outcome measure (see <a href="#CD006190-sec-0020">Types of outcome measures</a>); incomplete outcome data; selective outcome reporting; and other potential sources of bias (baseline imbalance and inappropriate administration of a co‐intervention), conforming to the methods recommended by Cochrane (<a href="./references#CD006190-bbs2-0037" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). To determine the risk of bias of a trial, we evaluated the presence of sufficient information and the likelihood of potential bias for each criterion. We rated each criterion as low risk of bias, high risk of bias or unclear risk of bias (either lacking information or uncertainty over the potential for bias). In a consensus meeting of review authors, we discussed and resolved disagreements with a third review author (RB). </p> </section> <section id="CD006190-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>To assess benefits, if available, we extracted raw data for outcomes of interest as well as number of participants. If reported data needed to be converted or imputed, we recorded this in the notes section of the table <a href="./references#CD006190-sec-0086" title="">Characteristics of included studies</a>. </p> <p>We plotted the results of each trial as risk ratios (RRs) with corresponding 95% confidence intervals (CIs) for dichotomous outcomes and as mean differences (MDs) between the intervention and comparator group, with corresponding 95% CIs for continuous data. The MD between treated group and control group is weighted by the inverse variance in the pooled treatment estimate. However, if different scales were used to measure the same conceptual outcome (e.g. functional status or pain), we calculated standardised mean differences (SMDs) instead, with corresponding 95% CIs. We calculated SMDs by dividing the MD by the standard deviation (SD), resulting in a unitless measure of treatment effect (<a href="./references#CD006190-bbs2-0031" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). </p> <p>In the <a href="#CD006190-sec-0056">Effects of interventions</a> section and the 'comments' column of the summary of findings table, we provided the absolute percentage difference, the relative percentage change from baseline, and the number needed to treat for an additional beneficial (NNTB) outcome, or the number needed to treat for an additional harmful outcome (NNTH) (NNTB or NNTH only for those outcomes with a clinically significant difference). For dichotomous outcomes, we calculated the absolute percentage change from the difference in the risks between the intervention and control group using GRADEpro GDT (<a href="./references#CD006190-bbs2-0035" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 8 September 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro 2015</a>), and expressed this as a percentage. We calculated the NNTB or the NNTH from the control group event rate and the RR using the Visual Rx NNT calculator (<a href="./references#CD006190-bbs2-0026" title="Visual Rx. Version 3. Dr. Chris Cates' EBM website, 2008. www.nntonline.net.">Cates 2008</a>). </p> <p>For continuous outcomes, we calculated the absolute benefit as the improvement in the intervention group minus the improvement in the control group, in the original units, expressed as a percentage. We calculated the relative percentage change for dichotomous data as the RR ‐ 1 and expressed this as a percentage. For continuous outcomes, we calculated the relative difference in the change from baseline as the absolute benefit divided by the baseline mean of the control group, expressed as a percentage. For continuous outcomes, we calculated the NNTB or NNTH using the Wells calculator software available at the Cochrane Musculoskeletal Group (CMSG) editorial office. We determined the minimal clinically important difference for each outcome for input into the calculator. </p> </section> <section id="CD006190-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>In the event that we identified cross‐over trials in which the reporting of continuous outcome data precluded paired analysis, we did not plan to include these data in a meta‐analysis, in order to avoid unit of analysis error. Where carry‐over effects were thought to exist, and where sufficient data existed, we planned to only include data regarding the first period in the analysis (<a href="./references#CD006190-bbs2-0038" title="HigginsJP , EldridgeS . Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021b</a>). However, we identified no cross‐over trials. </p> <p>For trials containing more than two intervention groups, to make multiple pair‐wise comparisons between all possible pairs of intervention groups possible, if data were available we planned to include the same group of participants only once in the same meta‐analysis. </p> </section> <section id="CD006190-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>In cases where individuals were missing from the reported results, we assumed the missing values to have a poor outcome. For dichotomous outcomes (e.g. number of withdrawals due to adverse events), we calculated the withdrawal rate using the number of participants randomised in the group as the denominator (worst case scenario). For continuous outcomes (e.g. mean change in pain score), we calculated the MD or SMD based on the number of participants analysed at that time point. If the number of participants analysed was not presented for each time point, we used the number of randomised participants in each group at baseline. </p> <p>Where possible, we computed missing SDs from other statistics such as standard errors (SEs), CIs or P values, according to the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006190-bbs2-0039" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021c</a>). If we could not calculate SDs, we imputed them, for example from other trials in the meta‐analysis. </p> </section> <section id="CD006190-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>Prior to meta‐analysis we assessed trials for clinical homogeneity with respect to type of therapy, control group and outcomes. For any trials judged as clinically homogeneous, we assessed statistical heterogeneity using I<sup>2</sup> statistics (<a href="./references#CD006190-bbs2-0031" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>), using the following as an approximate guide for interpretation: </p> <p> <ul id="CD006190-list-0006"> <li> <p>0% to 40% may not be important heterogeneity;</p> </li> <li> <p>30% to 60% may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90% may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100% may represent considerable heterogeneity.</p> </li> </ul> </p> <p>In cases of considerable heterogeneity (defined as I<sup>2</sup> &gt; 75%), we planned to explore the data further, including subgroup analyses, in an attempt to explain the heterogeneity. </p> </section> <section id="CD006190-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned an assessment of reporting bias through the screening of the International Clinical Trials Registry Platform of the World Health Organization (<a href="https://apps.who.int/trialsearch/Default.aspx" target="_blank">apps.who.int/trialsearch</a>; <a href="./references#CD006190-bbs2-0030" title="De AngelisCD , DrazenJM , FrizelleFA , HaugC , HoeyJ , HortonR , et al. Clinical Trial Registration: a statement from the International Committee of Medical Journal Editors. JAMA2004;292(11):1363-4.">De Angelis 2004</a>), to determine whether the protocols for included RCTs were published before recruitment of participants into the trial had started. We planned to evaluate whether selective reporting of outcomes was present (outcome reporting bias). </p> <p>We planned to compare the fixed‐effect estimate against the random‐effects model. In the event of the possible presence of small sample bias in the published literature (i.e. in which the intervention effect is more beneficial in smaller trials), the random‐effects estimate of the intervention is more beneficial than the fixed‐effect estimate (<a href="./references#CD006190-bbs2-0031" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). We planned to further explore the potential for reporting bias by funnel plots if more than 10 trials were included. </p> </section> <section id="CD006190-sec-0036"> <h4 class="title">Data synthesis</h4> <p>Where trials were sufficiently homogeneous that it remained clinically meaningful for them to be pooled, we performed meta‐analysis using a random‐effects model, regardless of the I<sup>2</sup> results. We performed analyses using Review Manager 5.4 (<a href="./references#CD006190-bbs2-0050" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a>), and produced forest plots for all analyses. </p> </section> <section id="CD006190-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform a subgroup analysis if data were available comparing treatment response for those with or without comorbidities. </p> <p>If data were available in the trials, we planned to extract data on subgroups and present data with subgroup totals. We planned to compare the magnitudes of the effects informally between the subgroups by means of assessing the overlap of the CIs of the effect estimate, however, there were insufficient data for this subgroup analysis. </p> </section> <section id="CD006190-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned sensitivity analyses for trials with regard to allocation concealment, blinding of outcome assessor and loss to follow‐up, comparing trials with limitations (low risk of bias versus high risk of bias or unclear risk of bias), however, there were insufficient data to perform sensitivity analyses. </p> </section> <section id="CD006190-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>The main results of the review are presented in a summary of findings table, which includes an overall grading of the evidence using the GRADE approach (<a href="./references#CD006190-bbs2-0035" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 8 September 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro 2015</a>), as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD006190-bbs2-0057" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Schünemann 2021</a>). We produced a summary of the available data for the main outcomes (pain, participant global assessment of treatment success, reduction in inflammation, function of target joint, serious adverse events, total adverse events and total number of withdrawals due to adverse events). </p> <p>Two review authors (BM and RJ) independently assessed the quality of the evidence using the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it related to the trials which contributed data to the meta‐analyses for the prespecified outcomes, and reported the quality of evidence as high, moderate, low, or very low. We used methods and recommendations described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006190-bbs2-0039" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021c</a>; <a href="./references#CD006190-bbs2-0057" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Schünemann 2021</a>). We justified all decisions to downgrade the quality of trials using footnotes and provided comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006190-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006190-sec-0040"></div> <section id="CD006190-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD006190-sec-0042"> <h4 class="title">Results of the search</h4> <p>Cochrane Musculoskeletal updated the search for all gout review updates on 28 August 2020, searching for trials from July 2011 to August 2020. The new search identified 4511 new records from Cochrane Central Register of Controlled Trials (CENTRAL) (849), MEDLINE (2125) and EMBASE (1537) databases. After screening titles and abstracts, we retrieved and reviewed the full text of 564 reports of studies potentially eligible for our gout reviews. </p> <p>Of these 564 full‐text reports, we excluded 562 (168 due to ineligible study design, 70 due to ineligible population, 315 due to ineligible intervention, three trials used an ineligible comparator, two were already included in the previous version of this review, and one was in an ineligible setting). </p> <p>We reviewed the remaining trials for eligibility for this review update and included two new trials (<a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>; <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>) in addition to two trials from the original review (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>; <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>). One additional trial is ongoing (<a href="./references#CD006190-bbs2-0018" title="TCTR20180608001. Comparing efficacy of loading and non-loading colchicine in acute crystal induced arthritis. www.thaiclinicaltrials.org 7 June 2018. ">TCTR20180608001</a>), and one trial that was awaiting assessment in the previous review has still not been published (<a href="./references#CD006190-bbs2-0017" title="WuYQ , HuJH , ZhaoZY , ZhouC , YuX , ZhengY , et al. Clinical observation on senile patients with acute gouty arthritis treated by acupoint application. Journal of the American Geriatrics Society2014;62(Suppl 2):S381. ">Wu 2014</a>). </p> <p>A flow diagram summarising the trial selection process is shown in <a href="#CD006190-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD006190-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006190-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006190-sec-0043"> <h4 class="title">Included studies</h4> <p>The four trials included in this updated review are described in the <a href="./references#CD006190-sec-0086" title="">Characteristics of included studies</a> table. </p> <section id="CD006190-sec-0044"> <h5 class="title">Study design, setting and characteristics</h5> <p>Two trials compared high‐dose colchicine to placebo (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>; <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>); one three‐arm trial also compared low‐dose colchicine to placebo and high‐dose to low‐dose colchicine (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>); one trial compared low‐dose colchicine to NSAIDs (<a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>); and one trial compared low‐dose colchicine to Chuanhu anti‐gout mixture (<a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>). The four included trials were conducted in different countries: Australia (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>), USA (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>), China (<a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>), and England (<a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>). Total duration of the trials varied from 48 hours in <a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a> to 12 weeks in <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>. One trial received funding from a pharmaceutical company who reported roles in the study design, data collection and writing of the manuscript (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>). One trial was funded by the hospital where the trial was conducted and reported a role in the study design, but no role in data collection, data analysis, data interpretation or report writing (<a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>). </p> </section> <section id="CD006190-sec-0045"> <h5 class="title">Study participants</h5> <p>The four trials included 803 randomised participants recruited from hospital and multicentre settings with trial sizes varying from 43 in <a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a> to 399 participants in <a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>. The majority of all trial participants were male, with mean age ranging from 51.2 to 70 years. </p> <p>Inclusion criteria varied across the trials but all four trials required a diagnosis of acute gout in adults, either by the identification of monosodium urate crystals in synovial fluid from joint aspirate assessed under polarised light microscopy (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>); diagnosis according to preliminary classification criteria of the American College of Rheumatology (ACR) with two flares within the past year (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>); a new diagnosis according to the 1977 preliminary classification criteria of the ACR and acute onset of gout of less than 48 hours (<a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>); or a clinical diagnosis of acute gout made by a general practitioner (GP) without joint aspiration, blood tests, imaging or diagnostic criteria (<a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>). <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> specified that women needed to be postmenopausal for eligibility (5% of trial participants). </p> </section> <section id="CD006190-sec-0046"> <h5 class="title">Interventions</h5> <p>Details of interventions for each trial are presented in the <a href="./references#CD006190-sec-0086" title="">Characteristics of included studies</a> tables. </p> <p>Treatments were administered orally for all trials and consisted of high‐dose colchicine (1 mg followed by 0.5 mg every 2 hours until complete response or adverse events) versus placebo (total dose not specified) (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>); high‐dose colchicine (4.8 mg over 6 hours) versus placebo (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>); low‐dose colchicine (1.8 mg over 1 hour) versus placebo (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>); high‐dose colchicine versus low‐dose colchicine (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>); low‐dose colchicine (0.5 mg 3 times per day for 4 days) versus NSAIDs (750 mg of naproxen at baseline then 250 mg every 8 hours for 7 days) (<a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>); or low‐dose colchicine (0.5 mg twice daily for 3 days, then 0.5 mg daily for 7 days) versus Chuanhu anti‐gout mixture (250 mL) (<a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>). </p> </section> <section id="CD006190-sec-0047"> <h5 class="title">Outcomes</h5> <section id="CD006190-sec-0048"> <h6 class="title">Pain</h6> <p>One trial measured pain using an 11‐point Numerical Rating Scale (0 no pain to 10 worst possible pain), which was self‐reported by participants daily from baseline to seven days and at trial endpoint (4 weeks) (<a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>). </p> <p><b>Participant global assessment of treatment success: proportion of participants with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours</b> </p> <p>Two trials measured pain on a 100‐point VAS (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>), and an 11‐point Likert scale (0 no pain to 10 worst possible pain; <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>), and these data were used to report participant global assessment of treatment success. <a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a> reported pain as a proportion of participants with 50% or greater improvement in pain from baseline at 12, 24, 36 and 48 hours. <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> reported the proportion of participants who responded to treatment, defined as a reduction in pain of 50% or more from baseline within 24 hours of the first trial dose. Alternate definitions of response for this trial included: (i) treatment response based on the target joint pain score 32 hours after the first dose, (ii) treatment response based on at least a two‐unit reduction in the target joint pain score 24 hours after the first dose, and (iii) treatment response based on at least a two‐unit reduction in the target joint pain score 32 hours after the first dose (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>). </p> <p><b>Reduction of inflammation (joint swelling/erythema/tenderness)</b> </p> <p>One trial used a compound clinical score comprised of pain, tenderness, redness and swelling (4‐point scale, 0 to 3 score recorded for each symptom with a maximum score of 12 per joint) to present inflammation as the proportion of participants with 50% or greater decrease in inflammation score from baseline to 32 to 26 hours (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>). </p> <p><a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a> reported biochemical marker changes for each study arm between baseline and 12‐week endpoint. </p> <p><b>Function of target joint</b> </p> <p>No trials reported function as an outcome.</p> <p><b>Serious and total adverse events</b> </p> <p>All trials reported on adverse events. All trials considered gastrointestinal events (diarrhoea, vomiting or nausea). <a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a> also considered headache, skin rash, and 'other' participant nominated adverse events. <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a> reported liver damage as an adverse event. <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> graded adverse events as mild, moderate, or severe based on a trial physician's clinical judgement in cases of acute gout flare. </p> <p><b>Withdrawals due to adverse events</b> </p> <p><a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> and <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a> reported the number of participants who withdrew from each study arm and the reason for withdrawal (including adverse events). <a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a> reported the number of participant withdrawals from the trial but did not provide reasons. <a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a> did not report withdrawals due to adverse events. </p> <p><b>Health‐related quality of life</b> </p> <p><a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a> measured participants' quality of life at baseline for each study arm using the EQ‐5D‐5L instrument, however, these data were used to calculate quality‐adjusted life‐years to determine the cost‐effectiveness of colchicine versus NSAIDs. Follow‐up data for quality of life using the EQ‐5D‐5L instrument were not reported for this trial. </p> <p>No other trials reported quality of life as an outcome.</p> </section> </section> </section> <section id="CD006190-sec-0049"> <h4 class="title">Excluded studies</h4> <p>A full description of excluded studies is provided in the <a href="./references#CD006190-sec-0087" title="">Characteristics of excluded studies</a> tables. Two studies were not RCTs (<a href="./references#CD006190-bbs2-0005" title="BlankN . Acute gouty arthropathy: treatment of acute gout attack with colchicine. Medizinische Klinik2010;105(9):669-70. ">Blank 2010</a>; <a href="./references#CD006190-bbs2-0010" title="MoonKT . Low-dose colchicine effective for acute gout flare-ups. American Family Physician2011;83(3):316. ">Moon 2011</a>), five did not include participants with acute gout (<a href="./references#CD006190-bbs2-0006" title="ChiCTR1800020315. Study for the effectiveness of different courses of low-dose colchicine for preventing acute flares during urate lowering therapy by febuxostat. www.chictr.org.cn/showproj.aspx?proj=32164 (first received 23 December 2018). ">ChiCTR1800020315</a>; <a href="./references#CD006190-bbs2-0008" title="KarimzadehH , NazariJ , MottaghiP , KabiriP . Different duration of colchicine for preventing recurrence of gouty arthritis. Journal of Research in Medical Sciences2006;11(2):104-7. ">Karimzadeh 2006</a>; <a href="./references#CD006190-bbs2-0011" title="PaulusHE , SchlossteinLH , GodfreyRG , KlinenbergJR , BluestoneR . Prophylactic colchicine therapy of intercritical gout. A placebo controlled study of probenecid treated patients. Arthritis and Rheumatism1974;17(5):609-14. ">Paulus 1974</a>; <a href="./references#CD006190-bbs2-0014" title="SchlesingerN , Lin H-Y, De MeulemeesterM , NasonovE , RovenskyJ , ArulmaniU , et al. Efficacy of canakinumab (ACZ885) in the prevention of flares in gout patients initiating allopurinol therapy. NDT Plus2010;3:iii3-4. SchlesingerN , MyslerE , LinH , De MeulemeesterM , RovenskyJ , ArulmaniU , et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Annals of the Rheumatic Diseases2011;70(7):1264-71. ">Schlesinger 2011</a>; <a href="./references#CD006190-bbs2-0015" title="YamanakaH , TamakiS , IdeY , KimH , InoueK , SugimotoM . Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Annals of the Rheumatic Diseases2018;77(2):270-6. ">Yamanaka 2018</a>), and five did not include colchicine as the intervention (<a href="./references#CD006190-bbs2-0007" title="HillE , HiggsJB , SkyK , SitM , CollamerAN . Does starting allopurinol prolong acute treated gout?Arthritis and Rheumatism2013;65(Suppl 10):S730. ">Hill 2013</a>; <a href="./references#CD006190-bbs2-0009" title="LiuY , Li Z-C, Chen J-B, Yu T-T, CuiC , Zhang H-B. Therapeutic efficacy of small doses of colchicine combined with glucocorticoid for acute gouty arthritis. People's Military Medical Press2015;40(8):652. ">Liu 2015</a>; <a href="./references#CD006190-bbs2-0012" title="RapadoA . Influence of atmospheric pressure on acute attacks of gout: negative findings. Revista Espanola de Reumatologia1975;2(4):188-93. ">Rapado 1975</a>; <a href="./references#CD006190-bbs2-0013" title="SchlesingerN , BakerDG , BeutlerAM , HoffmanBI , Schumacher Hr Jr. Local ice therapy during bouts of acute gouty arthritis. Journal of Rheumatology2002;29(2):331-4. ">Schlesinger 2002</a>; <a href="./references#CD006190-bbs2-0016" title="Yang D-H, Chen H-C, Wei JC-C. Early lowering of serum uric acid levels in the treatment of gouty arthritis with an acute attack. International Journal of Rheumatic Diseases2018;21(Suppl 1):218. ">Yang 2018</a>). </p> </section> </section> <section id="CD006190-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD006190-sec-0086" title="">Characteristics of included studies</a> tables. </p> <p>A risk of bias graph and a risk of bias summary can be seen in <a href="#CD006190-fig-0002">Figure 2</a> and <a href="#CD006190-fig-0003">Figure 3</a>, respectively. </p> <div class="figure" id="CD006190-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006190-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006190-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006190-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006190-sec-0051"> <h4 class="title">Allocation</h4> <p>We deemed three trials to have low risk of selection bias due to adequate random sequence generation, while <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> failed to describe the method of randomisation and so we deemed it unclear risk of selection bias. Allocation concealment was adequately reported for three trials, while we deemed <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a> at unclear risk of selection bias for not explicitly reporting the method of allocation concealment. </p> </section> <section id="CD006190-sec-0052"> <h4 class="title">Blinding</h4> <p>We judged three trials at low risk of performance and detection bias (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>; <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>; <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>), where blinding of trial participants and all trial personnel were adequately described for the comparison of high‐dose colchicine to placebo, low‐dose colchicine to placebo, high‐dose colchicine to low‐dose colchicine and low‐dose colchicine to Chuantu anti‐gout mixture. We judged <a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a> at high risk of performance and detection bias as participants and trial personnel were not blinded for the comparison between low‐dose colchicine and NSAIDs. </p> </section> <section id="CD006190-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>Risk of attrition bias was low in four trials (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>; <a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>; <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>; <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>). In <a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>, two out of 43 randomised participants were excluded from the trial due to difficulties understanding VAS, although the author did not specify their allocated treatment group. </p> <p>In <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>, there were similar numbers of participants across three treatment groups with incomplete data due to lack of benefit, loss to follow‐up or for other unclear reasons (7/52 (13.5%) in the high‐dose colchicine group, 3/74 (4%) in the low‐dose colchicine group and 4/59 (6.8%) in the placebo group). </p> <p>In <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>, three out of 88 participants (3.4%) in the Chuanhu group and nine out of 88 participants (10.2%) in the low‐dose colchicine group withdrew or were lost to follow‐up for reasons including diarrhoea, bitter taste, liver damage, broken blinding and poor compliance. </p> <p><a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a> reported a small number of participant withdrawals (0/199 in the low‐dose colchicine group and 3/200 (1.5%) in the NSAIDs group) and clinical trial unit withdrawals (4/199 (2%) in the low‐dose colchicine group and 4/200 (2%) in the NSAIDs group), however, reasons for withdrawal were not reported. The proportion of non‐responding participants was similar between treatment groups for data collected at eight time points throughout the trial. </p> </section> <section id="CD006190-sec-0054"> <h4 class="title">Selective reporting</h4> <p>We deemed three trials at low risk of reporting bias (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>; <a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>; <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>), and one trial at unclear risk of reporting bias (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>). </p> <p>We judged <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> to be at unclear risk of reporting bias due to pain scores not being presented, despite the methods stating that these data were collected. Additionally, a responder's analysis was presented for benefit. This trial was registered in 23 July 2007 but recruitment commenced in April 2007. </p> <p>Trial registration for <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a> was applied for retrospectively on 5 July 2013 and the trial ran from 1 September 2011 to 30 September 2012. All reported outcomes were included in the trial registration without modification. Data for two outcomes (scores for joint swelling and limitation of joint activity) were not reported, but were provided by the corresponding author upon request. </p> <p><a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a> did not provide any prespecified secondary outcome measures when registering the trial (NCT01994226), however, secondary outcomes were reported for time‐to‐treatment effect, complete pain resolution, self‐reported side effects, patient global assessment of treatment response, the use of additional medication for gout pain, self‐reported treatment adherence, relapse/recurrence of gout flare, quality of life (EQ‐5D‐5L), consultation/re‐attendance with health or medical professional for gout, and absence from work or education because of gout. </p> </section> <section id="CD006190-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p>We judged three trials to be at low risk of other potential sources of bias (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>; <a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>; <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>). </p> <p>We judged other potential sources of bias to be at unclear risk for <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> as the site of flare and number of joints affected was not presented, and if baseline differences existed this may have affected the results. The number of participants treated at each site was not specified but it is stated that some sites did not have participants in all treatment groups. While the number of randomised participants in each group was approximately equal, the number of participants in each group who had an acute flare of gout and therefore had outcome data available was not equal, which may have biased the data estimates. </p> </section> </section> <section id="CD006190-sec-0056"> <h3 class="title" id="CD006190-sec-0056">Effects of interventions</h3> <p>See: <a href="./full#CD006190-tbl-0001"><b>Summary of findings 1</b> Low‐dose colchicine versus placebo for acute gout</a>; <a href="./full#CD006190-tbl-0002"><b>Summary of findings 2</b> High‐dose colchicine versus placebo for acute gout</a>; <a href="./full#CD006190-tbl-0003"><b>Summary of findings 3</b> High‐dose versus low‐dose colchicine for acute gout</a>; <a href="./full#CD006190-tbl-0004"><b>Summary of findings 4</b> Low‐dose colchicine versus NSAIDs</a> </p> <p>We performed five comparisons: low‐dose colchicine versus placebo, high‐dose colchicine versus placebo, high‐dose versus low‐dose colchicine, low‐dose colchicine versus NSAIDs and low‐dose colchicine versus Chuanhu anti‐gout mixture. </p> <section id="CD006190-sec-0057"> <h4 class="title">Low‐dose colchicine versus placebo</h4> <p>Low‐quality evidence from one trial (103 participants) suggests that compared to placebo, low‐dose colchicine may slightly increase the number of people who report treatment success (pain reduction of 50% or more from baseline) at 32 to 36 hours; 31/74 in the low‐dose colchicine group reported treatment success compared to 5/29 in the placebo group (risk ratio (RR) 2.43, 95% confidence interval (CI) 1.05 to 5.64; 1 trial, 103 participants; absolute increase of 25% (7% more to 42% more), relative increase of 143% (5% more to 464% more), number needed to treat for an additional beneficial outcome (NNTB) 5 (2 to 39); low‐quality evidence; <a href="./full#CD006190-tbl-0001">summary of findings Table 1</a>; <a href="./references#CD006190-fig-0004" title="">Analysis 1.1</a>)). We downgraded the evidence for bias and imprecision. </p> <p>Low‐dose colchicine may have little or no effect on the number of people reporting adverse events. Up to 72 hours from baseline, there were 27/74 adverse events in the low‐dose colchicine group compared with 8/29 adverse events in the placebo group (RR 1.32, 95% CI 0.68 to 2.56; 1 trial; 103 participants; absolute difference 9% (9% fewer to 43% more), relative difference 32% (32% fewer to 156% more; low‐quality‐evidence; <a href="./full#CD006190-tbl-0001">summary of findings Table 1</a>; <a href="./references#CD006190-fig-0005" title="">Analysis 1.2</a>)). We downgraded the evidence for bias and imprecision. </p> <p>The <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> trial did not measure pain, reduction of inflammation or function of the target joint. The authors reported that there were no withdrawals due to adverse events and no serious adverse events in either treatment group. </p> </section> <section id="CD006190-sec-0058"> <h4 class="title">High‐dose colchicine versus placebo</h4> <p>We judged two trials to be clinically similar, facilitating the pooling of data for meta‐analysis. Participant global assessment of treatment success was presented by both trials as a proportion of participants with 50% or greater decrease in pain, where data were collected at 32 to 36 hours from baseline. Based upon data from the two trials (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>; <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>), there is low‐quality evidence (downgraded for selection and reporting bias and imprecision) that high‐dose colchicine may increase the number of people reporting treatment success when compared to placebo, with a clinically relevant proportion of participants reporting a reduction in pain of 50% or more from baseline at 32 to 36 hours; 35/74 reported treatment success in the high‐dose colchicine group compared with 12/50 (24%) in the placebo group (RR 2.16, 95% CI 1.28 to 3.65; I<sup>2</sup> = 0%; 2 trials, 124 participants; absolute difference 28% more success (8% more to 46% more), relative difference 116% (28% more to 265% more), NNTB 4 (3 to 12); low‐quality evidence; <a href="./full#CD006190-tbl-0002">summary of findings Table 2</a>; <a href="./references#CD006190-fig-0009" title="">Analysis 2.1</a>)). </p> <p>Low‐quality evidence (downgraded for bias and imprecision) from <a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a> demonstrates that high‐dose colchicine may increase the number of people with reduced inflammation. Reduction of inflammation was scored using a composite measure that included pain, tenderness, swelling and erythema; each graded on a 4‐point scale (0 = none to 3 = severe) to derive a maximum score of 12 in any one joint. At 36 hours, 11/22 people in the high‐dose colchicine reported 50% or greater decrease in inflammation score from baseline compared to 1/21 (5%) in the placebo group (RR 10.50, 95% CI 1.48 to 74.38; 1 trial, 43 participants; absolute difference 45% (22% greater to 68% greater), relative difference 950% (48% more to 7338% more), NNTB 3 (2 to 19); low‐quality evidence; <a href="./full#CD006190-tbl-0002">summary of findings Table 2</a>; <a href="./references#CD006190-fig-0010" title="">Analysis 2.2</a>)). </p> <p>Although the risk of adverse events was likely to have been inflated in the <a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a> trial due to the colchicine arm continually dosing participants every 2 hours until complete response or adverse events occurred, we pooled data from the two trials for total adverse events. Compared to placebo, there is low‐quality evidence that high‐dose colchicine may increase the number of people reporting adverse events; 62/74 (83%) in the high‐dose colchicine group reported adverse events compared to 13/50 (26%) in the placebo group (RR 3.21, 95% CI 2.01 to 5.11; 2 trials, 124 participants; absolute difference 57% (26% more to 74% more), relative difference 221% (101% more to 411% more), and number needed to treat for an additional harmful outcome (NNTH) 2 (2 to 10); low‐quality evidence; <a href="./full#CD006190-tbl-0002">summary of findings Table 2</a>; <a href="./references#CD006190-fig-0011" title="">Analysis 2.3</a>)). Assessing the <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> trial independently also provides low‐quality evidence that high‐dose colchicine may increase the number of adverse events compared with placebo; high‐dose colchicine: 40/52, placebo: 8/29 (RR 2.79, 95% CI 1.52 to 5.12; low‐quality evidence; <a href="./references#CD006190-fig-0011" title="">Analysis 2.3</a>). We downgraded evidence for bias and imprecision. </p> <p>Two trials comparing high‐dose colchicine and placebo did not report trial participant withdrawal due to serious adverse events, or withdrawals due to adverse events (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>; <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>). All 22 participants receiving high‐dose colchicine in <a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a> developed diarrhoea or vomiting, or both. <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> reported diarrhoea, nausea and vomiting for total adverse events (124 participants). <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> reported that there were no serious adverse events and <a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a> did not report whether adverse events occurred or not. </p> <p>The major outcomes, pain and function of target joint were not reported in the two trials comparing high‐dose colchicine to placebo. </p> </section> <section id="CD006190-sec-0059"> <h4 class="title">High‐dose versus low‐dose colchicine</h4> <p>Data from one trial (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>), found no evidence of important differences between high‐ and low‐dose colchicine for the proportion of participants who reported treatment success (reduction in pain of 50% or more from baseline). At 32 to 36 hours 19/52 (36%) (95% CI 23% to 57%) in the high‐dose colchicine group reported treatment success compared to 31/74 (42%) in the low‐dose colchicine group (RR 0.87, 95% CI 0.56 to 1.36; 1 trial, 126 participants; absolute difference 5% (23% fewer to 12% more), relative difference 13% (44% fewer to 136% more; low‐quality evidence; <a href="./full#CD006190-tbl-0003">summary of findings Table 3</a>; <a href="./references#CD006190-fig-0015" title="">Analysis 3.1</a>)). We downgraded evidence for bias and imprecision. </p> <p>Based on low‐quality evidence (downgraded for bias and imprecision) from one trial (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>), the number of participants reporting total adverse events may worsen with high‐dose colchicine (40/52 or 70%) compared to low‐dose colchicine (27/74 or 36%): RR 2.11, 95% CI 1.51 to 2.95; 1 trial, 126 participants; low‐quality evidence; absolute difference 41% (19% more to 71% more), relative difference 111% (51% more to 195% more), and NNTH 3 (2 to 5); <a href="./full#CD006190-tbl-0003">summary of findings Table 3</a>; <a href="./references#CD006190-fig-0016" title="">Analysis 3.2</a>. </p> <p>There were no withdrawals due to adverse events and no serious adverse events were reported in either arm of this trial. </p> <p>Outcomes for pain, reduction of inflammation or function of target joint were not measured. </p> </section> <section id="CD006190-sec-0060"> <h4 class="title">Low‐dose colchicine versus NSAIDs</h4> <p>Based on one trial with 399 participants (<a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>), colchicine may have little or no effect on pain when compared to NSAIDs at seven days (<a href="./references#CD006190-fig-0020" title="">Analysis 4.1</a>) Mean pain on a scale of 0 to 10 (0 is no pain) was 1.4 points on those taking NSAIDs and 1.5 points on those taking opioids; absolute difference 1% worse pain (3% better to 5% worse); relative change 1.4% worse (4% better to 7% worse). We downgraded the evidence to low quality for bias and imprecision. </p> <p>Low‐dose colchicine may have little or no effect on the number of people reporting treatment success compared to NSAIDs. At seven days 110/199 (55%, 95% CI 47% to 65%) in the low‐dose colchicine group reported treatment success compared to 114/200 in the NSAIDs group: RR 0.97, 95% CI 0.82 to 1.15; 1 trial, 399 participants; absolute difference 1.7% fewer people reported treatment success as completely better or much better with low‐dose colchicine (10.3% fewer to 8.5% more), compared to NSAIDs relative difference 3% (18% fewer to 15% more); low‐quality evidence; <a href="./references#CD006190-fig-0021" title="">Analysis 4.2</a>; <a href="./full#CD006190-tbl-0004">summary of findings Table 4</a>. We downgraded the evidence for bias and imprecision. </p> <p>This trial reported three serious adverse events (one in the low‐dose colchicine group and two in the NSAIDs group), however, none were related to trial interventions. There is little evidence of important differences for total adverse events between study arms (<a href="./references#CD006190-fig-0022" title="">Analysis 4.3</a>). There was one participant withdrawal in this trial, with reason not reported. </p> <p>Reduction of inflammation and function of target joint were not measured.</p> </section> <section id="CD006190-sec-0061"> <h4 class="title">Low‐dose colchicine versus Chuanhu anti‐gout mixture</h4> <p>Very low‐quality evidence from one trial (176 participants, downgraded two levels for imprecision and one level for risk of bias) found no evidence of important differences between low‐dose colchicine and Chuanhu anti‐gout mixture for recurrence rate of acute gout (<a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>); 13/88 in the low‐dose colchicine group reported recurrence compared to 11/88 in the Chuanhu anti‐gout mixture: RR 1.18, 95% CI 0.56 to 2.49; 1 trial, 176 participants; very low‐quality evidence; absolute difference 2.2% (5.5% fewer to 18.6% more), relative difference 18% (44% fewer to 149% more); <a href="./references#CD006190-fig-0024" title="">Analysis 5.1</a>. </p> <p>Based upon very low‐quality evidence, there were no important differences for withdrawal due to adverse events over 12 weeks between low‐dose colchicine (8/88) and Chunahu anti‐gout mixture (2/88): RR 4.00, 95% CI 0.87 to 18.31; absolute difference 6.8% (0.3% fewer to 39% more), relative difference 300% (13% fewer to 1731% more); <a href="./references#CD006190-fig-0025" title="">Analysis 5.2</a>. Based upon very low‐quality evidence, the total number of adverse events may significantly increase for participants taking low‐dose colchicine (27/88) versus Chuanhu anti‐gout mixture (2/88): RR 13.50, 95% CI 3.31 to 55.05, absolute difference 28% (5% more to 123% more), relative difference 1250% (231% more to 5405% more); <a href="./references#CD006190-fig-0026" title="">Analysis 5.3</a>. </p> <p>Lack of raw data for adverse reactions prevented comparisons to be made between low‐dose colchicine and Chuanhu anti‐gout mixture groups. </p> <p>No trials comparing low‐dose colchicine and Chuanhu anti‐gout mixture reported pain, participant global assessment of treatment success, reduction of inflammation or function of target joint. </p> <p>There were no trials that compared colchicine to glucocorticoids, which are known to be an effective treatment for acute gout. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006190-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006190-sec-0062"></div> <section id="CD006190-sec-0063"> <h3 class="title" id="CD006190-sec-0063">Summary of main results</h3> <p>Compared to placebo, there was low‐quality evidence that low‐dose colchicine may slightly increase the number of people who report treatment success at 32 to 36 hours from baseline, and low‐quality evidence suggesting that low‐dose colchicine may have little or no effect on the number of people reporting adverse events from treatment. It is unclear whether low‐dose colchicine increases the number of people with serious adverse events or the number of people withdrawing due to adverse events due to no events being reported for these outcomes (see <a href="./full#CD006190-tbl-0001">summary of findings Table 1</a>). None of the trials comparing low‐dose colchicine to placebo reported pain, reduction of inflammation or function of target joint. We downgraded the evidence due to the risk of selection or reporting bias, as well as imprecision. </p> <p>There was low‐quality evidence that compared to placebo, high‐dose colchicine may increase the number of people reporting treatment success, and increase the number of people with reduced inflammation at 32 to 36 hours from baseline. Low‐quality evidence also suggests that high‐dose colchicine may increase the number of people reporting adverse events when compared to placebo, which mostly consisted of diarrhoea, vomiting or nausea in two trials. There were no trials comparing high‐dose colchicine to placebo that reported pain or function of target joint. There were no serious adverse events or withdrawals due to adverse events reported in one trial, making it unclear whether high‐dose colchicine increases the number of people with these outcomes. We downgraded the evidence due to the risk of selection or reporting bias, as well as imprecision. </p> <p>Low‐quality evidence found that there may be no important differences for the proportion of people reporting treatment success between high‐dose colchicine and low‐dose colchicine, and suggests that high‐dose colchicine may increase the number of adverse events compared to low‐dose colchicine. It is uncertain whether high‐dose colchicine increases the number of people with serious adverse events or the number of people withdrawing due to adverse events compared to low‐dose colchicine, as one trial reported no events for these outcomes (see <a href="./full#CD006190-tbl-0003">summary of findings Table 3</a>). Trials comparing high‐dose colchicine to low‐dose colchicine did not report pain, reduction of inflammation or function of target joint outcomes. We downgraded the evidence due to the risk of selection or reporting bias, as well as imprecision. </p> <p>Based upon low‐quality evidence, low‐dose colchicine may have little or no effect on pain or the number of people reporting treatment success at seven days when compared to NSAIDs. One trial reported serious adverse events that were not related to any trial interventions. There was low‐quality evidence that low‐dose colchicine may make little or no difference to the number of adverse events compared to NSAIDs. We are uncertain whether low‐dose colchicine increases the number of withdrawals due to adverse events compared to NSAIDs, as low‐quality evidence from one trial reported one withdrawal in the low‐dose colchicine group without providing a reason. Trials comparing low‐dose colchicine to NSAIDs did not measure reduction of inflammation or function of target joint. We downgraded evidence from one trial due to risk of performance and detection bias in the trial's open‐label design. </p> <p>Very low‐quality evidence found no important differences for withdrawal due to adverse events between low‐dose colchicine and Chuanhu anti‐gout mixture over 12 weeks. Based upon very low‐quality evidence, low‐dose colchicine may increase the number of people reporting adverse events when compared to Chuanhu anti‐gout mixture. No trials comparing low‐dose colchicine and Chuanhu anti‐gout mixture reported pain, participant global assessment of treatment success, reduction of inflammation or function of target joint. We downgraded the evidence due to the risk of selection bias and imprecision. </p> </section> <section id="CD006190-sec-0064"> <h3 class="title" id="CD006190-sec-0064">Overall completeness and applicability of evidence</h3> <p>There are several treatment options for acute gout. When it comes to the use of colchicine, the overall balance of benefits and harms is key. We identified four trials investigating the benefits and harms of colchicine. One trial compared low‐dose colchicine to placebo, two trials compared high‐dose colchicine to placebo and one trial compared high‐dose to low‐dose colchicine. One trial compared low‐dose colchicine to NSAIDs, and one trial compared low‐dose colchicine to Chuanhu anti‐gout mixture. The data suggest that compared to placebo, low‐dose colchicine is as effective as higher doses of colchicine but with lower risk of adverse events. When compared to NSAIDs, low‐dose colchicine may have little or no effect on pain intensity, and may have little or no difference in the number of adverse events. </p> <p>Colchicine and its metabolites are excreted through the urinary and biliary tracts, and the presence of renal or liver disease increases the time needed for clearance of colchicine two‐ to three‐fold (<a href="./references#CD006190-bbs2-0024" title="Ben-ChetritE , LevyM . Colchicine: 1998 update. Seminars in Arthritis and Rheumatism1998;28:48-59.">Ben‐Chetrit 1998</a>). This suggests that people with either liver or renal disease may need to be closely monitored even while on low doses of colchicine. Three trials included in this review did not provide baseline participant hepatic or renal function data (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>; <a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>; <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>), however, one trial reported biochemical markers for liver and kidney function at baseline and 12‐week follow‐up (<a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>). <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a> reported that the risk of experiencing gastrointestinal events was similar when comparing demographic characteristics, concomitant allopurinol use or estimated creatinine clearance. </p> <p>The small number of included trials and trial participants means that uncommon but potentially serious adverse events may not have been detected. There have been reports of bone marrow and neuromuscular adverse events with the use of low‐dose colchicine (0.5 mg twice a day) (<a href="./references#CD006190-bbs2-0045" title="KunclR , DuncanG , WatsonD , AldersonK , RogawskiMA , PeperM . Colchicine myopathy and neuropathy. New England Journal of Medicine1987;316(25):1562-8.">Kuncl 1987</a>). </p> <p>We found no published trials of colchicine compared with oral or intra‐articular glucocorticoids.</p> <p>Colchicine can be administered intravenously to treat flares of acute gout. However, there is a narrow margin between an effective dose of the drug and a harmful dose that can result in serious health risks, including death. In February 2008, the US Food and Drug Administration (FDA) ruled that the manufacture or distribution of intravenous colchicine was no longer approved in the USA due to its adverse events (<a href="./references#CD006190-bbs2-0033" title="Food and Drug Administration. Drug products containing colchicine for injection; enforcement action dates. Federal Register (updated February 2008). Department of Health and Human Services, 2008. Available at www.federalregister.gov/documents/2008/02/08/08-564/drug-products-containing-colchicine-for-injection-enforcement-action-dates.">FDA 2008</a>). </p> <p>Colchicine is metabolised by cytochrome P450 3A4 (CYP3A4) and is also a substrate for the P‐glycoprotein transporter and serious (including fatal) colchicine adverse events have been reported in people taking standard therapeutic doses of colchicine and concomitantly prescribed medications that inhibit CYP3A4 or P‐glycoprotein (these include clarithromycin, erythromycin, ketoconazole, ritonavir, verapamil and diltiazem, among others). The US FDA recommends that these drugs not be used in people taking colchicine (particularly when there is coexisting renal of hepatic impairment) and, relatively recently, a dose reduction algorithm to predict and prevent colchicine adverse events in the presence of these drugs has been proposed (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>). </p> <p>In two of the included trials (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>; <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>), low‐dose colchicine consisted of a total of 1.8 mg given over one hour. For one trial (<a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>), the low‐dose colchicine consisted of 0.5 mg taken orally two times per day for three days, then 0.5 mg once per day for an additional seven days; and one trial provided participants with a 0.5 mg colchicine tablet (low‐dose) every eight hours for four days (<a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>). </p> </section> <section id="CD006190-sec-0065"> <h3 class="title" id="CD006190-sec-0065">Quality of the evidence</h3> <p>The overall quality of the evidence for the benefits and harms of colchicine for acute gout is low. Major outcomes for this review that were measured across four trials include: pain, patient global assessment of treatment success, reduction of inflammation and adverse events. Due to the small number of trials published on colchicine for acute gout and the variability of outcome measures used in the trials, pooling of data for meta‐analysis was only possible for two outcomes in two trials. There was the potential for selection bias and the risk of selective reporting in one trial, a high risk of performance and detection bias in one trial, and imprecision due to a small number of participants and events in the four trials. </p> </section> <section id="CD006190-sec-0066"> <h3 class="title" id="CD006190-sec-0066">Potential biases in the review process</h3> <p>We believe that our broad search strategy and database search identified all relevant trials, and minimised the likelihood of having missed any relevant trials. Two review authors independently assessed the trials for inclusion in the review and their risk of bias. </p> </section> <section id="CD006190-sec-0067"> <h3 class="title" id="CD006190-sec-0067">Agreements and disagreements with other studies or reviews</h3> <p>Our review updates a previous Cochrane Review (<a href="./references#CD006190-bbs2-0071" title="vanEchteldI , WechalekarMD , SchlesingerN , BuchbinderR , AletahaD . Colchicine for acute gout. Cochrane Database of Systematic Reviews2014, Issue 8. Art. No: CD006190. [DOI: 10.1002/14651858.CD006190.pub2]">van Echteld 2014</a>), and our conclusions are broadly in agreement with the previous update. </p> <p>Two systematic reviews synthesising evidence for the management of gout have been published since our previous update, although they examined slightly different questions (<a href="./references#CD006190-bbs2-0058" title="ShekellePG , NewberrySJ , FitzGeraldJD , MotalaA , O’HanlonCE , TariqA , et al. Management of gout: A systematic review in support of an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine2017;166:37-51. [DOI: 10.7326/M16-0461]">Shekelle 2017</a>; <a href="./references#CD006190-bbs2-0062" title="StewartS , YangKC , AtkinsK , DalbethN , RobinsonPC . Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Research &amp; Therapy2020;22:28.">Stewart 2020</a>). <a href="./references#CD006190-bbs2-0058" title="ShekellePG , NewberrySJ , FitzGeraldJD , MotalaA , O’HanlonCE , TariqA , et al. Management of gout: A systematic review in support of an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine2017;166:37-51. [DOI: 10.7326/M16-0461]">Shekelle 2017</a> reviewed the evidence for colchicine, NSAIDs and glucocorticoids in the management of acute gout flares. <a href="./references#CD006190-bbs2-0062" title="StewartS , YangKC , AtkinsK , DalbethN , RobinsonPC . Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Research &amp; Therapy2020;22:28.">Stewart 2020</a> synthesised adverse event data for oral colchicine used for any indication, including both chronic and acute gout. </p> <p><a href="./references#CD006190-bbs2-0058" title="ShekellePG , NewberrySJ , FitzGeraldJD , MotalaA , O’HanlonCE , TariqA , et al. Management of gout: A systematic review in support of an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine2017;166:37-51. [DOI: 10.7326/M16-0461]">Shekelle 2017</a> included 28 studies evaluating pharmacological treatments for acute gout, including only two of the four trials investigating the use of colchicine that we included (<a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a>; <a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>). It is unclear why <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a> was excluded as it is not listed as an excluded trial. <a href="./references#CD006190-bbs2-0062" title="StewartS , YangKC , AtkinsK , DalbethN , RobinsonPC . Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Research &amp; Therapy2020;22:28.">Stewart 2020</a> also included two of the four trials we included (<a href="./references#CD006190-bbs2-0003" title="FurstD , MaranianE , DavisP , WasonMW , KhannaS , TerkeltaubD . Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism2009;62(Suppl 10):147. TerkeltaubR , FurstD , BennettE , KookK , CrockettK , DavisRS , et al. Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism2010;60(Suppl 10):1103. TerkeltaubRA , FurstDE , BennettK , KookKA , CrockettRS , DavisMW . High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism2010;62(4):1060-8. WasonS , LauterioT , CrockettS , Davis, M. Colchicine, as assessed by target joint pain scores, is effective at 16 hours in patients with acute gout flares. Arthritis and Rheumatism2012;64(Suppl 10):S812. ">Terkeltaub 2010</a>; <a href="./references#CD006190-bbs2-0004" title="WangY , WangL , LiE , LiY , WangZ , SunX , et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. International Journal of Medical Sciences2014;11(9):880-5. ">Wang 2014</a>), but it was unclear why <a href="./references#CD006190-bbs2-0001" title="AhernMJ , ReidC , GordonTP . Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine1987;17:301-4. ">Ahern 1987</a> was not included. Neither review identified <a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a>, as their search dates preceded publication of the trial. </p> <p>The conclusions of both reviews in relation to colchicine are broadly in keeping with our updated review. <a href="./references#CD006190-bbs2-0058" title="ShekellePG , NewberrySJ , FitzGeraldJD , MotalaA , O’HanlonCE , TariqA , et al. Management of gout: A systematic review in support of an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine2017;166:37-51. [DOI: 10.7326/M16-0461]">Shekelle 2017</a> did not perform meta‐analyses and assessed the overall strength of evidence as high, moderate, low or insufficient but did not perform GRADE assessments. They also applied criteria proposed by Sir Austin Bradford Hill for causality when judging strength of evidence (<a href="./references#CD006190-bbs2-0040" title="HillAB . The environment and disease: association or causation?Proceedings of the Royal Society of Medicine1965;58(5):295-300.">Hill 1965</a>), although these criteria are usually applied to observational studies. <a href="./references#CD006190-bbs2-0062" title="StewartS , YangKC , AtkinsK , DalbethN , RobinsonPC . Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Research &amp; Therapy2020;22:28.">Stewart 2020</a> did not present data for the adverse events of colchicine for acute gout separately, but similarly to our review, reported that colchicine use was associated with an increased risk of diarrhoea and other gastrointestinal events. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006190-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006190-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006190-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006190-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low‐dose colchicine versus placebo, Outcome 1: Proportion with 50% or greater decrease in pain score from baseline" data-id="CD006190-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Low‐dose colchicine versus placebo, Outcome 1: Proportion with 50% or greater decrease in pain score from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low‐dose colchicine versus placebo, Outcome 2: Total adverse events" data-id="CD006190-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Low‐dose colchicine versus placebo, Outcome 2: Total adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low‐dose colchicine versus placebo, Outcome 3: Gastrointestinal adverse events (diarrhoea, vomiting or nausea)" data-id="CD006190-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Low‐dose colchicine versus placebo, Outcome 3: Gastrointestinal adverse events (diarrhoea, vomiting or nausea) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low‐dose colchicine versus placebo, Outcome 4: Serious adverse events" data-id="CD006190-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Low‐dose colchicine versus placebo, Outcome 4: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low‐dose colchicine versus placebo, Outcome 5: Withdrawals due to adverse events" data-id="CD006190-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Low‐dose colchicine versus placebo, Outcome 5: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High‐dose colchicine versus placebo, Outcome 1: Proportion with 50% or greater decrease in pain score from baseline" data-id="CD006190-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: High‐dose colchicine versus placebo, Outcome 1: Proportion with 50% or greater decrease in pain score from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High‐dose colchicine versus placebo, Outcome 2: Proportion with 50% or greater decrease in inflammation from baseline" data-id="CD006190-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: High‐dose colchicine versus placebo, Outcome 2: Proportion with 50% or greater decrease in inflammation from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High‐dose colchicine versus placebo, Outcome 3: Total adverse events" data-id="CD006190-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: High‐dose colchicine versus placebo, Outcome 3: Total adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High‐dose colchicine versus placebo, Outcome 4: Gastrointestinal adverse events (diarrhoea, vomiting or nausea)" data-id="CD006190-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: High‐dose colchicine versus placebo, Outcome 4: Gastrointestinal adverse events (diarrhoea, vomiting or nausea) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High‐dose colchicine versus placebo, Outcome 5: Serious adverse events" data-id="CD006190-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: High‐dose colchicine versus placebo, Outcome 5: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High‐dose colchicine versus placebo, Outcome 6: Withdrawals due to adverse events" data-id="CD006190-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: High‐dose colchicine versus placebo, Outcome 6: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose versus low‐dose colchicine, Outcome 1: Proportion with 50% or greater decrease in pain score from baseline" data-id="CD006190-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: High‐dose versus low‐dose colchicine, Outcome 1: Proportion with 50% or greater decrease in pain score from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose versus low‐dose colchicine, Outcome 2: Total adverse events" data-id="CD006190-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: High‐dose versus low‐dose colchicine, Outcome 2: Total adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose versus low‐dose colchicine, Outcome 3: Gastrointestinal adverse events (diarrhoea, vomiting or nausea)" data-id="CD006190-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: High‐dose versus low‐dose colchicine, Outcome 3: Gastrointestinal adverse events (diarrhoea, vomiting or nausea) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose versus low‐dose colchicine, Outcome 4: Serious adverse events" data-id="CD006190-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: High‐dose versus low‐dose colchicine, Outcome 4: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose versus low‐dose colchicine, Outcome 5: Withdrawals due to adverse events" data-id="CD006190-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: High‐dose versus low‐dose colchicine, Outcome 5: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Low‐dose colchicine versus NSAIDs, Outcome 1: Absolute mean pain (NRS 0 to 10)" data-id="CD006190-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Low‐dose colchicine versus NSAIDs, Outcome 1: Absolute mean pain (NRS 0 to 10) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Low‐dose colchicine versus NSAIDs, Outcome 2: Participant global assessment of treatment success (Completely better/much better)" data-id="CD006190-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Low‐dose colchicine versus NSAIDs, Outcome 2: Participant global assessment of treatment success (Completely better/much better) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Low‐dose colchicine versus NSAIDs, Outcome 3: Total adverse events at 4 weeks" data-id="CD006190-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Low‐dose colchicine versus NSAIDs, Outcome 3: Total adverse events at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Low‐dose colchicine versus NSAIDs, Outcome 4: Serious adverse events" data-id="CD006190-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Low‐dose colchicine versus NSAIDs, Outcome 4: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Low‐dose colchicine versus Chuanhu anti‐gout mixture, Outcome 1: Recurrence rate of gout at 12 weeks" data-id="CD006190-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Low‐dose colchicine versus Chuanhu anti‐gout mixture, Outcome 1: Recurrence rate of gout at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Low‐dose colchicine versus Chuanhu anti‐gout mixture, Outcome 2: Withdrawals due to adverse events" data-id="CD006190-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Low‐dose colchicine versus Chuanhu anti‐gout mixture, Outcome 2: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Low‐dose colchicine versus Chuanhu anti‐gout mixture, Outcome 3: Total adverse events" data-id="CD006190-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Low‐dose colchicine versus Chuanhu anti‐gout mixture, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006190-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/urn:x-wiley:14651858:media:CD006190:CD006190-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Low‐dose colchicine versus Chuanhu anti‐gout mixture, Outcome 4: Serious adverse events" data-id="CD006190-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_t/tCD006190-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Low‐dose colchicine versus Chuanhu anti‐gout mixture, Outcome 4: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/media/CDSR/CD006190/image_n/nCD006190-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006190-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Low‐dose colchicine versus placebo for acute gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Low‐dose colchicine versus placebo for acute gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with acute gout<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> low‐dose colchicine versus placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control (placebo)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Low‐dose colchicine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant global assessment of treatment success:</b> proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>418 per 1000</b><br/>(181 to 970) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b> <br/>(1.05 to 5.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose colchicine may slightly increase the number of people who report treatment success. </p> <p>Absolute difference: 25% more reported success (7% more to 42% more);</p> <p>relative percentage change: 143% (5% more to 464% more)</p> <p>NNTB 5 (2 to 39)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of inflammation</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function of target joint</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants reported no serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>276 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b><br/>(188 to 706) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> <br/>(0.68 to 2.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose colchicine may have little or no effect on the number of people reporting adverse events. </p> <p>Absolute difference: 9% more events with low‐dose colchicine (11% fewer to 29% more), compared to placebo. </p> <p>Relative percentage change: 32% more events (32% fewer to 156% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participants withdrew due to adverse events in either study arm.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB</b> : number needed to treat for an additional beneficial outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to a risk of selection bias from unclear reporting of the method of randomisation, and a risk of reporting bias.<br/><sup>b</sup>Downgraded one level for imprecision as the number of events was small (&lt; 200) and 95% CI includes no effect, or appreciable benefit.<br/><sup>c</sup>Note: number needed to treat for an additional beneficial (NNTB) or harmful outcome (NNTH) is not reported when result is not statistically significant. Number needed to treat for dichotomous outcomes calculated using 1/risk difference for single studies and Cates NNT calculator for meta‐analyses (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Low‐dose colchicine versus placebo for acute gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006190-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">High‐dose colchicine versus placebo for acute gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>High‐dose colchicine versus placebo for acute gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with acute gout<br/><b>Settings:</b> hospital and outpatient<br/><b>Intervention:</b> high‐dose colchicine versus placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control (Placebo)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>High‐dose colchicine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant global assessment of treatment success:</b> proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>518 per 1000</b><br/>(307 to 876) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.16</b> <br/>(1.28 to 3.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose colchicine may increase the number of people reporting treatment success.</p> <p>Absolute difference: 28% more reported success (8% more to 46% more);</p> <p>relative percentage change: 116% (28% more to 265% more).</p> <p>NNTB: 4 (3 to 12)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of inflammation:</b> proportion with 50% or greater decrease in inflammation score from baseline ‐ 32 to 36 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>504 per 1000</b><br/>(278 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 10.50</b> (1.48 to 74.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose colchicine may increase the number of people with reduced inflammation.</p> <p>Absolute difference: 45% greater reduction of inflammation with colchicine (22% greater to 68% greater). </p> <p>Relative percentage change: 950% (48% more to 7338% more)</p> <p>NNTB: 3 (2 to 19)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function of target joint</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported that there were no serious adverse events and one study did not report whether any serious adverse events occurred or not. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>829 per 1000</b><br/>(520 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.21</b> <br/>(2.01 to 5.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose colchicine may increase the number of people reporting adverse events.</p> <p>Absolute difference: 57% more events with high‐dose colchicine (26% more to 74% more), compared to placebo. </p> <p>Relative percentage change: 221% (101% more to 411% more).</p> <p>NNTH: 2 (2 to 10)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported that there were no withdrawals due to adverse events and one study did not report whether withdrawals due to adverse events occurred or not. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB</b> : number needed to treat for an additional beneficial outcome; <b>NNTH</b> : number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to a risk of selection bias from unclear reporting of the method of randomisation, and a risk of reporting bias in one study.<br/><sup>b</sup>Downgraded one level for imprecision as the total number of participants is small and the total number of events is small.<br/><sup>c</sup>Note: number needed to treat for an additional beneficial (NNTB) or harmful outcome (NNTH) is reported when the difference between treatment and control is statistically significant, calculated using Cates NNT calculator for dichotomous outcomes (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">High‐dose colchicine versus placebo for acute gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006190-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High‐dose versus low‐dose colchicine for acute gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>High‐dose versus low‐dose colchicine for acute gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with acute gout<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> high‐dose versus low‐dose colchicine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control (low‐dose colchicine)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>High‐dose colchicine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant global assessment of treatment success:</b> proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>419 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b><br/>(235 to 570) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> <br/>(0.56 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests little to no difference for the proportion of people reporting treatment success between high‐dose colchicine and low‐dose colchicine. </p> <p>Absolute difference: 5% fewer reported success (23% fewer to 12% more).</p> <p>Relative percentage change: 13% fewer (44% fewer to 136% more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of inflammation</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function of target joint</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported that there were no serious adverse events in either study arm.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>770 per 1000</b><br/>(551 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.11</b> <br/>(1.51 to 2.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose colchicine may increase the number of adverse events compared to low‐dose colchicine. </p> <p>Absolute difference: 41% more events with high‐dose (19% more to 71% more), compared to low‐dose colchicine. </p> <p>Relative percentage change: 111% more events (51% more to 195% more).</p> <p>NNTH: 3 (2 to 5)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported that there were no withdrawals due to adverse events in either study arm. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTH</b> : number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to a risk of selection bias from unclear reporting of the method of randomisation, and a risk of reporting bias.<br/><sup>b</sup>Downgraded one level for imprecision as the number of events was small (&lt; 200) and 95% CI includes no effect, or appreciable benefit.<br/><sup>c</sup>Note: number needed to treat for an additional beneficial (NNTB) or harmful outcome (NNTH) is reported when the difference between treatment and control is statistically significant, calculated using Cates NNT calculator for dichotomous outcomes (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High‐dose versus low‐dose colchicine for acute gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006190-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Low‐dose colchicine versus NSAIDs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Low‐dose colchicine versus NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with acute gout<br/><b>Settings:</b> 100 GPs across England<br/><b>Intervention:</b> low‐dose colchicine versus naproxen </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control (NSAIDs)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Low‐dose colchicine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>NRS Scale from 0 to 10, 0 is no pain.</p> <p>Follow‐up: 7 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain was 0.1 points worse (0.29 better to 0.49 worse)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>399</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose colchicine may have little or no effect on pain when compared to NSAIDs.</p> <p>Absolute difference: 1% worse pain (3% better to 5% worse).</p> <p>Relative percentage change: 1.4% worse (4% better to 7% worse)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant global assessment of treatment success:</b> </p> <p>Completely better/much better</p> <p>Follow‐up: 7 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>570 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>553 per 1000</b><br/>(467 to 655) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b><br/>(0.82 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>399</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose colchicine may have little or no effect on the number of people reporting treatment success. </p> <p>Absolute difference: 1.7% fewer people reported treatment success as completely better or much better with low‐dose colchicine (10.3% fewer to 8.5% more), compared to NSAIDs. Relative percentage change: 3% fewer (18% fewer to 15% more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of inflammation</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function of target joint</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were three serious adverse events (2 from the NSAIDs group and 1 from low‐dose colchicine group), none related to study interventions, and no deaths. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants reporting adverse events</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>535 per 1000</b><br/>(440 to 645) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b><br/>(0.88 to 1.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>399</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose colchicine may have little or no difference to the number of adverse events compared to NSAIDs. </p> <p>Absolute difference: 3.5% more people reported adverse events (6% fewer to 14.5% more), compared to NSAIDs. Relative percentage change: 7% (12% fewer to 29% more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was one withdrawal from the low‐dose colchicine group with the reason unreported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>GPs</b> : general practices; <b>NRS</b> : numeric rating scale; <b>NSAIDs</b> : non‐steroidal anti‐inflammatory drugs; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to a risk of performance and detection bias.<br/><sup>b</sup>Downgraded one level for imprecision as the number of events was small (&lt; 200) and 95% CI includes no effect, or appreciable benefit. Data were from a single study only, which may have been inadequately powered to detect a clinically important change in pain between groups (defined as 1.5 points on the 0 to 10 NRS pain scale).<br/><sup>c</sup>Relative change was calculated as absolute change (mean difference) divided by mean at baseline in the NSAIDs group from <a href="./references#CD006190-bbs2-0002" title="RoddyE , ClarksonK , Blagojevic-BucknallM , MehtaR , OppongR , AveryA , et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases2020;79:276-84. ">Roddy 2020</a> (mean NRS baseline value was 7.1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Low‐dose colchicine versus NSAIDs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/full#CD006190-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006190-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Low‐dose colchicine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Proportion with 50% or greater decrease in pain score from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 32 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Gastrointestinal adverse events (diarrhoea, vomiting or nausea) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Low‐dose colchicine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006190-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High‐dose colchicine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Proportion with 50% or greater decrease in pain score from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.52, 10.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.88 [1.28, 6.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 32 to 36 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [1.28, 3.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.05, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 Last time point</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [1.20, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Proportion with 50% or greater decrease in inflammation from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 36 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [2.01, 5.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Gastrointestinal adverse events (diarrhoea, vomiting or nausea) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.81 [2.28, 6.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High‐dose colchicine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006190-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">High‐dose versus low‐dose colchicine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Proportion with 50% or greater decrease in pain score from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 32 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Gastrointestinal adverse events (diarrhoea, vomiting or nausea) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">High‐dose versus low‐dose colchicine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006190-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Low‐dose colchicine versus NSAIDs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Absolute mean pain (NRS 0 to 10) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Participant global assessment of treatment success (Completely better/much better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Total adverse events at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Low‐dose colchicine versus NSAIDs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006190-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Low‐dose colchicine versus Chuanhu anti‐gout mixture</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Recurrence rate of gout at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Low‐dose colchicine versus Chuanhu anti‐gout mixture</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006190.pub3/references#CD006190-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006190.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD006190-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD006190-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006190-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006190-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD006190-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD006190-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD006190-note-0015">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD006190-note-0011">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006190-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006190\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006190\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006190\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006190\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006190.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006190.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006190.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006190.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006190.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727310746"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006190.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727310750"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006190.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea8f53f989377',t:'MTc0MDcyNzMxMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 